var title_f14_14_14560="Narrow Deaver retractor";
var content_f14_14_14560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Narrow Deaver retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14560=[""].join("\n");
var outline_f14_14_14560=null;
var title_f14_14_14561="Inferior alveolar block";
var content_f14_14_14561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inferior alveolar nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 522px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When administering the inferior alveolar block, the target area (*) lies on the medial surface of the mandibular ramus. The needle is inserted parallel to the mandibular occlusal plane (A), with the syringe overlying the first and second premolars on the opposite side of the mandible; the syringe is rotated approximately 30 degrees (in a horizontal plane) during the injection so that when the injection is complete, the syringe barrel rests on the anterior teeth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14561=[""].join("\n");
var outline_f14_14_14561=null;
var title_f14_14_14562="Patient information: Myasthenia gravis (The Basics)";
var content_f14_14_14562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/23/26994\">",
"         Patient information: Dysarthria (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/13/7378\">",
"         Patient information: Dysphagia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/34/15906\">",
"         Patient information: Hyperkalemia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/13/34001\">",
"         Patient information: Muscular dystrophy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/10/33954\">",
"         Patient information: Periodic paralysis syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/13/41168\">",
"         Patient information: Bell's palsy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Myasthenia gravis (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H78151879\">",
"      <span class=\"h1\">",
"       What is myasthenia gravis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Myasthenia gravis (called &ldquo;MG&rdquo; here) is a condition that causes weakness in certain muscles. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Muscles in the eyelids and around the eyes &ndash; If MG only affects these muscles, doctors call it &ldquo;ocular myasthenia gravis.&rdquo; About half of all people with MG have this type.",
"       </li>",
"       <li>",
"        Jaw muscles",
"       </li>",
"       <li>",
"        Arm or leg muscles",
"       </li>",
"       <li>",
"        Muscles that help with breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Myasthenia gravis happens when the body&rsquo;s infection-fighting system, called the &ldquo;immune system,&rdquo; makes proteins called &ldquo;antibodies.&rdquo; The antibodies attack the connections between nerves and muscles by mistake.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H78151894\">",
"      <span class=\"h1\">",
"       What are the symptoms of myasthenia gravis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is muscle weakness. It can come and go, and is often worse later in the day. It can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Droopy eyelids",
"       </li>",
"       <li>",
"        Blurry vision or double vision",
"       </li>",
"       <li>",
"        Trouble chewing food - The jaw muscles might feel tired about halfway through a meal.",
"       </li>",
"       <li>",
"        Trouble swallowing",
"       </li>",
"       <li>",
"        Trouble talking &ndash; A person might speak in a lower voice than usual, or sound like he or she has a cold or stuffy nose.",
"       </li>",
"       <li>",
"        Loss of expression on the face",
"       </li>",
"       <li>",
"        Head that feels heavy or drops forward",
"       </li>",
"       <li>",
"        Trouble breathing &ndash; A person might feel short of breath, take extra breaths, or feel like it takes a lot of effort to breathe.",
"       </li>",
"       <li>",
"        Weakness &ndash; It might be hard to lift the arms or legs, open the fingers, or lift a foot.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H78151909\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will do an exam and learn about your symptoms. You might also have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Electrical tests of nerves and muscles &ndash; These can show if nerves are carrying electrical signals normally and if muscles are responding correctly to electrical signals.",
"       </li>",
"       <li>",
"        Imaging tests, such as CT or MRI scans &ndash; Most people with myasthenia gravis have some changes in the thymus gland. This is a gland in the chest that is part of the immune system. Imaging tests can show changes, including a tumor on the thymus gland. Some people have a CT scan or MRI of the head. It can show if a different condition is causing symptoms.",
"       </li>",
"       <li>",
"        A test with a medicine called",
"        <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"         edrophonium",
"        </a>",
"        (brand names: Enlon, Tensilon) &ndash; Doctors give this through a tube called an &ldquo;IV&rdquo; that goes into a vein. If the medicine helps the eye and eyelid muscles work better, it could be a sign of MG.",
"       </li>",
"       <li>",
"        Ice pack test &ndash; During this test, a doctor puts a cool pack on the eyelids. If the eyelids open better after resting under the cool pack, this could be a sign of MG.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H78151926\">",
"      <span class=\"h1\">",
"       How is myasthenia gravis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to treat muscle weakness &ndash; Such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?38/53/39764?source=see_link\">",
"         pyridostigmine",
"        </a>",
"        (sample brand names: Mestinon, Regonol).",
"       </li>",
"       <li>",
"        Medicines that treat the immune system over time &ndash; Such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/31/28149?source=see_link\">",
"         azathioprine",
"        </a>",
"        (brand names: Azasan, Imuran).",
"       </li>",
"       <li>",
"        Fast-acting immune system treatments &ndash; Such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A medicine called &ldquo;intravenous immunoglobulin&rdquo; (IVIG) &ndash; This medicine is given through an IV.",
"       </li>",
"       <li>",
"        Plasma exchange (also called &ldquo;plasmapheresis&rdquo;) &ndash; For this treatment, a machine pumps blood from the body and removes substances from the blood that are attacking the nerves and muscles. Then the machine returns the blood to the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery to remove the thymus gland",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If MG attacks the muscles that help with breathing, it can cause severe breathing problems. These are usually treated in the intensive care unit (also called the &ldquo;ICU&rdquo;).",
"     </p>",
"     <p>",
"      Children with MG can take some of the same medicines as adults. But some medicines used to treat MG can cause more serious problems in children if used for a long time. Surgery to remove the thymus gland is safe for children and often works well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H78151942\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk to your doctor or nurse before you start trying to have a baby. Pregnancy can make MG worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H78151957\">",
"      <span class=\"h1\">",
"       What else should I know about myasthenia gravis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have MG that affects more than just the eyes can have serious problems if they get the flu or pneumonia. For this reason, it is especially important that they get the flu shot every year and the pneumonia vaccine at least 1 time.",
"     </p>",
"     <p>",
"      Some medicines can make MG worse. Talk to your doctor or nurse before you take any medicines, including over-the-counter medicines. If you get a prescription for a new medicine, ask if it is safe to take when you have MG.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H78151972\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/23/26994?source=see_link\">",
"       Patient information: Dysarthria (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=see_link\">",
"       Patient information: Dysphagia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/34/15906?source=see_link\">",
"       Patient information: Hyperkalemia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=see_link\">",
"       Patient information: Muscular dystrophy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=see_link\">",
"       Patient information: Periodic paralysis syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/13/41168?source=see_link\">",
"       Patient information: Bell's palsy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/14/14562?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86724 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14562=[""].join("\n");
var outline_f14_14_14562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H78151879\">",
"      What is myasthenia gravis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H78151894\">",
"      What are the symptoms of myasthenia gravis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H78151909\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H78151926\">",
"      How is myasthenia gravis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H78151942\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H78151957\">",
"      What else should I know about myasthenia gravis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H78151972\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/13/41168?source=related_link\">",
"      Patient information: Bell's palsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/23/26994?source=related_link\">",
"      Patient information: Dysarthria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=related_link\">",
"      Patient information: Dysphagia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/34/15906?source=related_link\">",
"      Patient information: Hyperkalemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=related_link\">",
"      Patient information: Muscular dystrophy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=related_link\">",
"      Patient information: Periodic paralysis syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_14_14563="Uterine septum at hysteroscopy";
var content_f14_14_14563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Uterine septum separating uterine cavity into two horns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14563=[""].join("\n");
var outline_f14_14_14563=null;
var title_f14_14_14564="Methylcellulose: Patient drug information";
var content_f14_14_14564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methylcellulose: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     see \"Methylcellulose: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Citrucel&reg; [OTC];",
"     </li>",
"     <li>",
"      Soluble Fiber Therapy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to raise fiber in the diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methylcellulose or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly cramps.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11502 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14564=[""].join("\n");
var outline_f14_14_14564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194960\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023036\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023035\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023040\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023041\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023043\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023038\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023039\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023044\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023045\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=related_link\">",
"      Methylcellulose: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_14_14565="Gingival avulsion repair";
var content_f14_14_14565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Gingival avulsion repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 652px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Pass suture through tip of flap on the facial portion of the gum and pass needle through the teeth to the palatal portion of the gum. If the teeth are too close together to permit passage of the needle floss the suture between the teeth and then take a bite through the palatal portion of the gums (inset).",
"    <br>",
"     (B) Pass the needle circumferentially around the tooth to the facial side of the gum so that it comes out through the flap and tie. If the teeth are too close to permit passage of the needle, floss the suture between the teeth to the facial portion of the gums, take a bite of tissue, and then tie (inset). For edentulous patients be sure that the suture knots and loops are not located in regions of contact with the bridge.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14565=[""].join("\n");
var outline_f14_14_14565=null;
var title_f14_14_14566="Blood supply of the adrenal glands";
var content_f14_14_14566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Blood supply of the adrenal glands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 473px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three main groups of vessels supply the adrenal gland: the superior suprarenal arteries, derived from the inferior phrenic arteries; the middle suprarenal artery, derived from the aorta; and the inferior suprarenal renal arteries, derived from the adjacent renal artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14566=[""].join("\n");
var outline_f14_14_14566=null;
var title_f14_14_14567="Vasodilator therapy in severe chronic aortic regurgitation in adults";
var content_f14_14_14567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vasodilator therapy in severe chronic aortic regurgitation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14567/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14567/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14567/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14567/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14567/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/14/14567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with chronic aortic regurgitation (AR, also called aortic insufficiency) are generally managed in a conservative fashion and surgery is postponed until the patient develops symptoms, left ventricular (LV) systolic dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe LV dilatation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vasodilator therapy in patients with severe chronic AR is aimed at reducing the hemodynamic burden by reducing regurgitant volume. However, the efficacy of vasodilator therapy has",
"    <strong>",
"     not",
"    </strong>",
"    been established in asymptomatic AR as a means of mitigating changes in LV size and function and delaying the onset of symptoms and thus the need for corrective surgery.",
"   </p>",
"   <p>",
"    The role of vasodilator therapy in chronic severe AR in adults will be reviewed here. Issues related to the pathophysiology, clinical features, and course and management of chronic AR and to acute AR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among asymptomatic patients with chronic AR and normal LV systolic function (ie, normal left ventricular ejection fraction [LVEF]), the likelihood of progressing to symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    LV dysfunction ranges from 0 to 19 percent per year according to the absence or presence of LV dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enlargement as determined in part from the LV end-systolic dimension (",
"    <a class=\"graphic graphic_table graphicRef54569 \" href=\"UTD.htm?0/37/604\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Values above 55-60 mm are considered to reflect a decompensated state (",
"    <a class=\"graphic graphic_table graphicRef69635 \" href=\"UTD.htm?7/8/7308\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H2#H2\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Prognosis and course'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As will be described below, vasodilator therapy should be considered only in patients with",
"    <strong>",
"     severe",
"    </strong>",
"    chronic AR and LV dilation (",
"    <a class=\"graphic graphic_table graphicRef79823 \" href=\"UTD.htm?4/39/4732\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/1\">",
"     1",
"    </a>",
"    ]. There is no evidence of benefit in patients with mild to moderate AR.",
"   </p>",
"   <p>",
"    On physical examination, severe AR is characterized by a longer diastolic murmur, a displaced LV impulse, a wide pulse pressure, and the peripheral findings of a wide pulse pressure such as a water hammer (Corrigan's) pulse and other signs such as a head bob occurring with each heart beat (deMusset's sign). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link&amp;anchor=H13#H13\">",
"     \"Examination of the arterial pulse\", section on 'Water hammer pulse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the accuracy of physical examination is not reliable and a hemodynamic definition, usually by echocardiography, is the recommended method for determining the severity of AR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=see_link&amp;anchor=H17#H17\">",
"     \"Echocardiographic evaluation of the aortic valve\", section on 'Aortic regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For clinical purposes, the importance of defining severe chronic AR in asymptomatic patients is to identify those who might be candidates for more frequent monitoring. Almost all patients with chronic severe AR have or will develop LV dilation. Only severe AR is likely to produce LV dilation. Thus, one should look for other causes, such as a cardiomyopathy, when LV dilation is present in patients with mild to moderate AR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF REGURGITANT VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regurgitant volume in aortic regurgitation is determined by two factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The magnitude and duration of the diastolic pressure gradient across the valve.",
"     </li>",
"     <li>",
"      The effective regurgitant orifice area. It has been assumed that the regurgitant orifice area is constant, but this notion may not be valid in patients with disease of the aortic root.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the LV ejection fraction, systemic vascular resistance, systolic blood pressure, and ventricular afterload are",
"    <strong>",
"     not",
"    </strong>",
"    direct determinants of the regurgitant volume.",
"   </p>",
"   <p>",
"    The duration of diastole is primarily a function of heart rate; as a result, bradycardia will increase AR flow [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Although pacing-induced tachycardia offers little benefit to patients with chronic AR, clinicians should be aware of the potential danger of bradycardia.",
"   </p>",
"   <p>",
"    The other major determinant of regurgitant volume is the transvalvular pressure gradient throughout diastole. This provides a rationale for treating hypertension and reducing the aortic diastolic pressure in patients with AR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS AND STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small clinical trials have provided some evidence of benefit from vasodilators in asymptomatic patients with chronic severe aortic regurgitation and LV dilation, since these are the patients at risk for progression (",
"    <a class=\"graphic graphic_table graphicRef54569 \" href=\"UTD.htm?0/37/604\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/1\">",
"     1",
"    </a>",
"    ]. However, some studies have found no benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nifedipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    therapy was studied in an initial randomized, double blind, placebo-controlled trial of 72 asymptomatic patients in Italy with chronic severe AR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/6\">",
"     6",
"    </a>",
"    ]. After 12 months, nifedipine (20 mg twice daily), reduced the systolic pressure and LV volume, and increased the ejection fraction. The only change in the placebo group was a small decrease in the ejection fraction. All study patients remained asymptomatic and none required surgery during the follow-up period.",
"   </p>",
"   <p>",
"    In a subsequent report, the same investigators followed the course of 143 asymptomatic patients with isolated severe AR (mean blood pressure",
"    <span class=\"nowrap\">",
"     152/59",
"    </span>",
"    mmHg) and normal LV function (mean LVEF 63 percent) who were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (20 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    (0.25",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    the trial was not blinded [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/7\">",
"     7",
"    </a>",
"    ]. The following benefits were noted in the nifedipine group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first year, valve replacement was not required in any patient treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      compared to approximately 6 percent of those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      After six years, as determined by actuarial analysis, valve replacement was required significantly less often in the patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (15 versus 34 percent) (",
"      <a class=\"graphic graphic_figure graphicRef73071 \" href=\"UTD.htm?20/28/20941\">",
"       figure 1",
"      </a>",
"      ). The patients who underwent valve replacement, independent of which drug was used, had a fall in LVEF from 62 percent at baseline to 46 percent before surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the design of this study, one cannot distinguish between a beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and a deleterious effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . In addition, it is possible that the nonblinded nature affected the results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Outcome after AVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evidence supporting benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    therapy comes from a third study from the same group showing evidence of improved outcomes after surgery in those patients who progress and require aortic valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/8\">",
"     8",
"    </a>",
"    ]. 266 patients in randomized trials of nifedipine versus placebo in asymptomatic patients with a normal LVEF progressed to left ventricular dysfunction and underwent aortic valve replacement. The following were main findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean duration of therapy before surgery was much longer with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (16 versus 3 years with placebo), again showing slowed progression.",
"     </li>",
"     <li>",
"      Although the two surgical groups were hemodynamically similar at baseline, the LVEF normalized in all patients who had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      , but remained low in 28 percent of those who had not.",
"     </li>",
"     <li>",
"      At 10 year follow-up, the LVEF (62 versus 48 percent) and patient survival (85 versus 78 percent) were significantly higher in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism(s) by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    therapy before surgery might improve long-term outcomes after surgery are not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small randomized trials and studies of ACE inhibitors in patients with chronic AR have shown inconsistent evidence of benefit as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 76 patients with asymptomatic AR were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/9\">",
"       9",
"      </a>",
"      ]. After one year, a decrease in arterial pressure was seen in both groups. The patients receiving enalapril (31",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      showed a decrease in ventricular chamber size, whereas there was no significant change in those treated with hydralazine (177",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"     <li>",
"      These positive findings were not confirmed in a randomized trial comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      (25 mg three times daily for six months) to placebo in 23 patients with isolated severe AR [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/11\">",
"       11",
"      </a>",
"      ]. There was no change in either arterial pressure or ventricular chamber size in the patients treated with captopril.",
"     </li>",
"     <li>",
"      As described below, no benefit was seen from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      therapy in a long-term randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, an observational study of 2,266 patients with at least moderate AR found an association between treatment with ACE inhibitors or angiotensin II receptor blocker (ARB) therapy and reduced all-cause mortality, fewer cardiovascular events, and fewer AR events (heart failure hospitalization, heart failure death, or aortic valve replacement) at mean 4.4 year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/12\">",
"     12",
"    </a>",
"    ]. While this result suggests a potential role for ACE inhibitor or ARB therapy in patients with AR, the mechanism of benefit was not addressed. Randomized, prospective, controlled clinical trials are needed to determine if ACE inhibitor treatment might be beneficial in adults with chronic aortic regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hydralazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two trials evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    in chronic AR. In one, 45 largely asymptomatic patients were randomly assigned to hydralazine or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/14\">",
"     14",
"    </a>",
"    ]. Hydralazine, at an average dose of 215",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    did not affect blood pressure or heart rate. At 24 months, hydralazine therapy was associated with a significant decrease in ventricular volume and increase in LVEF",
"   </p>",
"   <p>",
"    In contrast, no evidence of improvement in left ventricular size or function was noted at 12 months in the second trial (cited above) in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    (average dose 177",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/9\">",
"     9",
"    </a>",
"    ]. There is no obvious reason for these disparate results, except perhaps that the dose of hydralazine and the duration of treatment differed in the two studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Comparative trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to more clearly define the role of vasodilators, 95 consecutive patients with asymptomatic severe chronic AR (mean blood pressure",
"    <span class=\"nowrap\">",
"     144/76",
"    </span>",
"    mmHg) and an LVEF &ge;50 percent were randomly assigned to open-label therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (20 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with other valve disease, hypertension, atrial fibrillation, coronary disease, Marfan syndrome, or an ascending aortic aneurysm were excluded. Predefined criteria for aortic valve replacement were the onset of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an LVEF &lt;50 percent or an end-systolic dimension &ge;50 mm that were confirmed by a second examination.",
"   </p>",
"   <p>",
"    At a mean follow-up of seven years, there was no significant difference in the three groups in the rate of aortic valve replacement (41 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , 50 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , and 39 percent in the control group), or in LVEF, left ventricular size or mass, or the regurgitant volume. At one year after aortic valve replacement, all patients had a normal LVEF and the left ventricular end-systolic and end-diastolic diameters had fallen to a similar degree in the three treatment groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Possible explanations for conflicting data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Why the comparative trial did not replicate the beneficial effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    in the Italian studies cited above, including the persistence of benefit from preoperative therapy after aortic valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], is not clear. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Nifedipine'",
"    </a>",
"    above.) The following explanations have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mechanism of benefit in the randomized Italian trial is uncertain, since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      did not reduce the left ventricular end-systolic volume or increase the LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/7\">",
"       7",
"      </a>",
"      ], both of which might be expected with a reduction in afterload. Furthermore, the control group in this trial was treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , not placebo.",
"     </li>",
"     <li>",
"      The doses used may have been too low in the comparative trial, since there was no effect on blood pressure or regurgitant severity in either of the treatment groups [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/13\">",
"       13",
"      </a>",
"      ]. However, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      dose was the same as used in the Italian trials (20 mg twice daily).",
"     </li>",
"     <li>",
"      The patients in the comparative trial may have had less severe disease as suggested by a much lower pulse pressure (68 versus 93 mmHg).",
"     </li>",
"     <li>",
"      The comparative trial may have been underpowered to detect a benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical trial and study summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasodilators have the potential to reduce the hemodynamic burden on the volume-loaded left ventricle in severe AR. However, randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and ACE inhibitors have produced conflicting findings as to whether there is [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/13\">",
"     13",
"    </a>",
"    ] a benefit from vasodilator therapy. Although less well studied, data are also conflicting about the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THERAPEUTIC DECISIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular guidelines (with 2008 focused update) include the following recommendations for vasodilator therapy for AR (",
"    <a class=\"graphic graphic_table graphicRef79823 \" href=\"UTD.htm?4/39/4732\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasodilator therapy is indicated for patients with severe AR with symptoms or LV dysfunction when surgery is not recommended because of additional cardiac or noncardiac factors.",
"     </li>",
"     <li>",
"      Vasodilator therapy is reasonable for short-term therapy to improve the hemodynamic profile of patients with AR with severe heart failure symptoms and severe LV dysfunction before proceeding with AVR.",
"     </li>",
"     <li>",
"      Effectiveness is less well established for long-term vasodilator therapy in asymptomatic patients with severe AR and LV dilatation with normal systolic function.",
"     </li>",
"     <li>",
"      Vasodilator therapy is not indicated for long-term therapy in asymptomatic patients with mild to moderate AR and normal LV systolic function.",
"     </li>",
"     <li>",
"      Vasodilator therapy is not indicated for long-term therapy in potential candidates for AVR including asymptomatic patients with LV systolic dysfunction and symptomatic patients with either normal LV function or mildly to moderately depressed LV systolic function; instead these patients should be promptly referred for valve replacement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H21#H21\">",
"       \"Course and management of chronic aortic regurgitation in adults\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2007 by the European Society of Cardiology (ESC) valvular guidelines include the following conclusions regarding vasodilator therapy for chronic AR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with chronic severe AR and heart failure, ACE inhibitors are the treatment of choice when surgery is contraindicated or in cases with persistent postoperative LV dysfunction.",
"     </li>",
"     <li>",
"      In asymptomatic patients with AR with high blood pressure, treatment of hypertension with vasodilators such as ACE inhibitors or dihydropyridine calcium channel blockers is warranted.",
"     </li>",
"     <li>",
"      The role of vasodilators is unproven as a means of delaying surgery in asymptomatic non-hypertensive patients with AR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the above",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular guideline recommendations (",
"    <a class=\"graphic graphic_table graphicRef79823 \" href=\"UTD.htm?4/39/4732\">",
"     table 3",
"    </a>",
"    ). In addition, we suggest long-term vasodilator therapy in asymptomatic patients with hypertension and any degree of AR as recommended in the ESC guidelines. This includes the systolic hypertension associated with severe chronic AR, which can increase systolic wall stress and reduce forward stroke volume [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/16\">",
"     16",
"    </a>",
"    ]. However, as noted in the comparative trial, it is often difficult to substantially lower the systolic pressure with vasodilators in patients with severe AR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a vasodilator is indicated, the optimal drug remains uncertain. The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and European Society of Cardiology guidelines do not specify a vasodilator choice for asymptomatic AR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, the benefits of ACE inhibitors in patients with other causes of asymptomatic or symptomatic ventricular dilation suggest that these agents may also be of greater value in patients with AR.",
"   </p>",
"   <p>",
"    As a result, many cardiologists use ACE inhibitors rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    when vasodilator therapy is given. Treatment is started at a low dose and titrated to the typical dose used for heart failure, as tolerated by blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H20#H20\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Dose titration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of other antihypertensive drugs for blood pressure control in patients with chronic AR treated with an ACE inhibitor or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    is not well studied. Once a patient is on maximal ACE inhibitor therapy, we would add other antihypertensive drugs only for a diastolic pressure over 90 mmHg, which would be rare in severe AR, and possibly for a systolic pressure over 160 mmHg. However, a high systolic pressure is common in severe AR and is often difficult to lower.",
"   </p>",
"   <p>",
"    If further antihypertensive drug therapy is given, we suggest avoiding beta blockers. By slowing the heart rate, beta blockers prolong diastole, thereby increasing the diastolic regurgitant time and the regurgitant volume per beat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with chronic aortic regurgitation (AR, also called aortic insufficiency) are generally managed in a conservative fashion unless they develop an indication for aortic valve replacement (usually symptoms or LV dysfunction). Conservative therapy includes periodic monitoring for progressive disease that would fulfill criteria for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials have produced conflicting findings as to whether there is or is not a benefit from vasodilator therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical trials and studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recognizing the limitations of the data, we treat as follows. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Therapeutic decisions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest long-term vasodilator therapy in asymptomatic patients with hypertension and any degree of AR (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This includes the systolic hypertension associated with severe chronic AR, which can increase wall stress [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/16\">",
"       16",
"      </a>",
"      ]. However, it is often difficult to lower the blood pressure with vasodilators in patients with severe AR [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14567/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       against",
"      </strong>",
"      long-term vasodilator therapy in patients who are not at risk for progression including those with mild to moderate AR and those with what appears to be severe AR without LV enlargement (",
"      <a class=\"graphic graphic_table graphicRef54569 \" href=\"UTD.htm?0/37/604\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Determinants of prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a vasodilator is given, we suggest an ACE inhibitor in preference to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Treatment is started at a low dose and titrated to the typical dose used for heart failure, as tolerated by blood pressure. Nifedipine is an acceptable alternative to an ACE inhibitor.",
"     </li>",
"     <li>",
"      Whether or not vasodilators are used, it is imperative to follow the patient closely in order to detect the earliest symptoms or exercise intolerance, and to perform serial studies of LV size and function. The development of symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      LV systolic dysfunction are indications for aortic valve replacement or aortic valve repair (",
"      <a class=\"graphic graphic_table graphicRef81155 graphicRef57010 \" href=\"UTD.htm?22/44/23245\">",
"       table 4A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"       \"Course and management of chronic aortic regurgitation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend vasodilator therapy for patients with severe AR with symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      LV dysfunction when surgery is not recommended because of additional cardiac issues or noncardiac comorbidities (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest vasodilator therapy as short-term therapy for patients with AR with severe heart failure and LV dysfunction before proceeding with AVR (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/1\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/2\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/3\">",
"      Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol 1996; 28:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/4\">",
"      Judge TP, Kennedy JW, Bennett LJ, et al. Quantitative hemodynamic effects of heart rate in aortic regurgitation. Circulation 1971; 44:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/5\">",
"      Firth BG, Dehmer GJ, Nicod P, et al. Effect of increasing heart rate in patients with aortic regurgitation. Effect of incremental atrial pacing on scintigraphic, hemodynamic and thermodilution measurements. Am J Cardiol 1982; 49:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/6\">",
"      Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S. Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation. J Am Coll Cardiol 1990; 16:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/7\">",
"      Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994; 331:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/8\">",
"      Scognamiglio R, Negut C, Palisi M, et al. Long-term survival and functional results after aortic valve replacement in asymptomatic patients with chronic severe aortic regurgitation and left ventricular dysfunction. J Am Coll Cardiol 2005; 45:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/9\">",
"      Lin M, Chiang HT, Lin SL, et al. Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll Cardiol 1994; 24:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/10\">",
"      Sch&ouml;n HR, Dorn R, Barthel P, Sch&ouml;mig A. Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation. J Heart Valve Dis 1994; 3:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/11\">",
"      Wisenbaugh T, Sinovich V, Dullabh A, Sareli P. Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis 1994; 3:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/12\">",
"      Elder DH, Wei L, Szwejkowski BR, et al. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol 2011; 58:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/13\">",
"      Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005; 353:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/14\">",
"      Greenberg B, Massie B, Bristow JD, et al. Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial. Circulation 1988; 78:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/15\">",
"      Carabello BA. Vasodilators in aortic regurgitation--where is the evidence of their effectiveness? N Engl J Med 2005; 353:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14567/abstract/16\">",
"      Bekeredjian R, Grayburn PA. Valvular heart disease: aortic regurgitation. Circulation 2005; 112:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8142 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14567=[""].join("\n");
var outline_f14_14_14567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DETERMINANTS OF REGURGITANT VOLUME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL TRIALS AND STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nifedipine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Outcome after AVR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hydralazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Comparative trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Possible explanations for conflicting data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical trial and study summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THERAPEUTIC DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8142\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8142|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/28/20941\" title=\"figure 1\">",
"      Nifedipine in AR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8142|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/37/604\" title=\"table 1\">",
"      Natural history of chronic AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/8/7308\" title=\"table 2\">",
"      Stages of aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/39/4732\" title=\"table 3\">",
"      Vasodilators in chronic AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/53/24412\" title=\"table 4A\">",
"      ACC AHA AVR in chronic AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/4/40011\" title=\"table 4B\">",
"      AV surgery in chronic AR young",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_14_14568="Treatment of metabolic alkalosis";
var content_f14_14_14568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of metabolic alkalosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14568/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14568/contributors\">",
"     Ankit Mehta, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14568/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14568/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14568/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/14/14568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9857747\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic alkalosis is characterized by a primary rise in the plasma bicarbonate concentration which leads to an increase in arterial pH. Two factors are required for the genesis and then maintenance of metabolic alkalosis: a process that raises the plasma bicarbonate concentration, and a process that prevents excretion of the excess bicarbonate in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Treatment of metabolic alkalosis should be aimed at reversing these two factors.",
"   </p>",
"   <p>",
"    This topic will provide a brief overview of the pathogenesis of metabolic alkalosis followed by a discussion of how to treat affected patients. The pathogenesis of metabolic alkalosis is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link\">",
"     \"Pathogenesis of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology and evaluation of patients with metabolic alkalosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link\">",
"     \"Clinical manifestations and evaluation of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1039092\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THE PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two factors are required for the genesis and then maintenance of metabolic alkalosis: a process that raises the plasma bicarbonate concentration, and a process that prevents excretion of the excess bicarbonate in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9319111\">",
"    <span class=\"h2\">",
"     Factors that increase plasma bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanisms for a primary increase in the plasma bicarbonate concentration are as follows (",
"    <a class=\"graphic graphic_table graphicRef57489 \" href=\"UTD.htm?26/4/26699\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrogen loss due to removal of gastric secretions (as with vomiting or tube drainage) or to increased urinary acid secretion (due, for example, to loop or thiazide diuretics or primary mineralocorticoid excess).",
"     </li>",
"     <li>",
"      Shift of hydrogen ions from the extracellular fluid into the cells, which is most often due to hypokalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A less common cause is contraction alkalosis due to the loss of relatively large volumes of bicarbonate-free fluid, as with loop diuretic therapy in a patient with marked edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9319118\">",
"    <span class=\"h2\">",
"     Factors that impair bicarbonate excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of impaired bicarbonate excretion for maintenance of metabolic alkalosis was illustrated in a study of adults who had a gastric or duodenal ulcer and were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    at a dose ranging from 10 to 20",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    per day (approximately 1000",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    for two to three weeks. These large doses of sodium bicarbonate produced only a small elevation in the plasma bicarbonate concentration of approximately 3 to 4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    because nearly all of the excess bicarbonate was excreted in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common cause of impaired bicarbonate excretion in patients with metabolic alkalosis is a reduction in the effective arterial blood volume (EABV, also called effective circulating volume), which is a nonmeasurable entity that refers to the arterial volume which perfuses the tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/1\">",
"     1",
"    </a>",
"    ]. A reduction in EABV stimulates the kidney to retain sodium; this also limits the excretion of bicarbonate, which is excreted as sodium (or potassium) bicarbonate in order to maintain electroneutrality. The net effect is that patients may have a paradoxically acid urine (paradoxical aciduria) despite the presence of metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common causes of a reduced EABV are true volume depletion (eg, vomiting or diuretic therapy) and decreased tissue perfusion caused by reduced cardiac output in heart failure and systemic vasodilation in cirrhosis.",
"   </p>",
"   <p>",
"    Other causes of impaired bicarbonate excretion include hypokalemia, chloride depletion (which may be a major contributing factor in most patients with reduced EABV), and acute and chronic kidney disease. Metabolic acidosis is the usual acid-base disorder that occurs in patients with reduced kidney function as a result of impaired acid excretion. However, if such patients develop metabolic alkalosis as a result of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ingestion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting, then the \"excess\" bicarbonate cannot be readily excreted due to the kidney disorder. The mechanisms by which these changes occur are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of metabolic alkalosis\", section on 'Hypokalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of metabolic alkalosis\", section on 'Chloride depletion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9857754\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of metabolic alkalosis should be aimed at reversing the etiology of bicarbonate generation and reversing those factors that prevent the kidneys from excreting the excess bicarbonate. In order to accomplish this, two questions must be answered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the increase in plasma bicarbonate concentration due to gastrointestinal or renal hydrogen ion loss (eg, vomiting, diuretic therapy), contraction of the extracellular fluid volume, an intracellular shift of hydrogen ions, an exogenous load of alkali or alkali precursors, or a combination of these factors (",
"      <a class=\"graphic graphic_table graphicRef57489 \" href=\"UTD.htm?26/4/26699\">",
"       table 1",
"      </a>",
"      )?",
"     </li>",
"     <li>",
"      Why is the excess bicarbonate not being excreted in the urine? As mentioned above, the major causes of reduced renal bicarbonate excretion are reduced effective arterial blood volume, hypokalemia, chloride depletion, and acute and chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H9319118\">",
"       'Factors that impair bicarbonate excretion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1863594\">",
"    <span class=\"h2\">",
"     Treat the underlying cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying etiology of the alkalosis should be reversed (eg, treating the cause of vomiting, stopping or slowing the removal of gastric secretions, reducing the acid content of the gastrointestinal secretions, and stopping loop or thiazide diuretics). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of metabolic alkalosis\", section on 'Gastrointestinal hydrogen loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who develop metabolic alkalosis as a result of persistent vomiting or gastric suction can be effectively treated with drugs that reduce gastric HCl secretion. Both H2 blockers and proton pump inhibitors have been utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All exogenous sources of alkali should be discontinued to the extent possible. This includes bicarbonate therapy and the administration of the sodium or potassium salts of any organic anion that is metabolized to bicarbonate, such as citrate or lactate. Bicarbonate administration to patients with organic metabolic acidosis (usually lactic or ketoacidosis) can also be considered \"excess\" bicarbonate, resulting in a \"rebound\" or post correction metabolic alkalosis. This occurs because, after correction of the hypotension or insulin deficiency, the lactate and beta-hydroxybutyrate can be subsequently oxidized to regenerate bicarbonate. Thus, the exogenously administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    will then represent \"excess\" bicarbonate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Bicarbonate and metabolic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypokalemia, if present, should be reversed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of metabolic alkalosis\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1863671\">",
"    <span class=\"h2\">",
"     Enhance renal bicarbonate excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance of metabolic alkalosis requires a reduction in the renal excretion of the excess bicarbonate. Reversing the factors that impair renal bicarbonate excretion will correct the alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of metabolic alkalosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important factors that impair renal bicarbonate excretion include (see",
"    <a class=\"local\" href=\"#H9319118\">",
"     'Factors that impair bicarbonate excretion'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A reduced effective arterial blood volume (EABV)",
"     </li>",
"     <li>",
"      Chloride depletion and hypochloremia",
"     </li>",
"     <li>",
"      Potassium depletion and hypokalemia",
"     </li>",
"     <li>",
"      Reduced kidney function",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1863706\">",
"    <span class=\"h3\">",
"     Reduced effective arterial blood volume and chloride depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced EABV and chloride depletion usually occur simultaneously. If the EABV depletion can be treated with isotonic saline (sodium chloride), this will simultaneously restore arterial volume and correct the chloride deficit.",
"   </p>",
"   <p>",
"    All forms of EABV depletion promote persistence of metabolic alkalosis since the kidney is stimulated to retain sodium, and this limits the ability to excrete bicarbonate. EABV depletion includes true volume depletion (eg, vomiting, nasogastric suction, diuretic therapy, or rarely villous adenoma) (",
"    <a class=\"graphic graphic_table graphicRef57489 \" href=\"UTD.htm?26/4/26699\">",
"     table 1",
"    </a>",
"    ) as well as decreased arterial filling due to reduced cardiac output in heart failure or systemic vasodilation in cirrhosis. These later causes of low EABV do not respond to saline volume expansion, and such treatment often results in further deterioration. (See",
"    <a class=\"local\" href=\"#H9319118\">",
"     'Factors that impair bicarbonate excretion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1864356\">",
"    <span class=\"h4\">",
"     True volume depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with true volume depletion, but not in heart failure and cirrhosis, the metabolic alkalosis should be corrected by fluid repletion, usually with isotonic saline. A reasonable regimen in patients with mild to moderate hypovolemia is to administer isotonic saline at a rate that is about 100",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    greater than the urine output plus other fluid losses that may be present (eg, gastrointestinal losses). More aggressive therapy is required in patients with severe hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link&amp;anchor=H10#H10\">",
"     \"Maintenance and replacement fluid therapy in adults\", section on 'Rate of repletion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Rate of fluid repletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate repletion of the extracellular and intravascular volume has the following beneficial effects in patients with metabolic alkalosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in proximal and distal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      reabsorption, which will increase urinary bicarbonate excretion.",
"     </li>",
"     <li>",
"      A reduction in proximal chloride reabsorption, resulting in increased chloride delivery to the distal nephron.",
"     </li>",
"     <li>",
"      The increase in distal chloride delivery will promote connecting segment and collecting tubule bicarbonate secretion via the chloride-bicarbonate anion exchanger (pendrin) located on the luminal surface of type B intercalated cells (",
"      <a class=\"graphic graphic_figure graphicRef62465 \" href=\"UTD.htm?17/31/17917\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/4,7-10\">",
"       4,7-10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The resulting increase in bicarbonate excretion should be reflected by an alkaline urine pH, which will be above 7 when significant bicarbonaturia exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1864600\">",
"    <span class=\"h4\">",
"     Edematous states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with edematous states such as heart failure, cirrhosis, nephrotic syndrome, and cor pulmonale can develop metabolic alkalosis. This is often due to diuretic therapy. Treatment with isotonic saline is generally",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in edematous patients for two reasons: it will increase edema, ascites,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    effusions; and it will",
"    <strong>",
"     not",
"    </strong>",
"    correct the metabolic alkalosis since the underlying renal sodium avidity will persist, limiting urinary excretion of the excess bicarbonate. These patients are usually hypokalemic and potassium depleted. In such patients, the metabolic alkalosis is often improved or even corrected by administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    . The addition of potassium-sparing diuretics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    may also be helpful. (See",
"    <a class=\"local\" href=\"#H9857783\">",
"     'Potassium depletion'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30503?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles of the treatment of edema in adults\", section on 'Use of diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to potassium-sparing diuretics, patients with heart failure or cirrhosis are often treated with an aldosterone antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ). However, their use must be carefully monitored to avoid development of potentially life-threatening hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Diuretic regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If additional diuresis is required, the carbonic anhydrase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , can be administered (250 to 500 mg, once or twice a day) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/1\">",
"     1",
"    </a>",
"    ]. Acetazolamide is a carbonic anhydrase inhibitor that preferentially inhibits proximal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    reabsorption, thereby increasing urinary bicarbonate excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39128?source=see_link&amp;anchor=H6#H6\">",
"     \"Mechanism of action of diuretics\", section on 'Acetazolamide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , the increase in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    delivery to the potassium-secretory site in the collecting tubules will enhance potassium secretion. The resulting kaliuresis can cause or worsen hypokalemia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     Potassium chloride",
"    </a>",
"    replacement may be necessary. There are also a variety of contraindications to acetazolamide therapy. These include hypersensitivity to sulfonamides, liver disease, hypokalemia (as noted), and severe kidney disease. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     \"Acetazolamide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1864673\">",
"    <span class=\"h4\">",
"     Chloride depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, sodium and potassium should be given with chloride to correct metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Delivery of sodium and chloride to the distal nephron results in the reabsorption of both sodium and chloride as well as chloride reabsorption in exchange for bicarbonate in the connecting segment and collecting tubules by a luminal",
"    <span class=\"nowrap\">",
"     chloride/bicarbonate",
"    </span>",
"    exchanger called pendrin (",
"    <a class=\"graphic graphic_figure graphicRef62465 \" href=\"UTD.htm?17/31/17917\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Whether resolution of hypovolemia or repletion of the chloride deficit is the key factor responsible for correcting metabolic alkalosis is the subject of ongoing debate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/7\">",
"     7",
"    </a>",
"    ]. Some evidence from experimental models supports the chloride repletion hypothesis. In the absence of volume expansion, for example, administration of chloride salts with a non-sodium cation (such as choline chloride) corrects the metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/12\">",
"     12",
"    </a>",
"    ], but administration of sodium salts with a non-chloride anion (such as sulfate or nitrate) does not [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Although sulfate and nitrate are freely filtered and delivered to the distal renal tubules, they are not readily reabsorbed; reabsorption of sodium without an accompanying anion allows the anion to be excreted with ammonium (NH4), titratable acid (H2PO4),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    potassium, preventing correction of the metabolic alkalosis and further depleting potassium stores [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9857783\">",
"    <span class=\"h3\">",
"     Potassium depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    is an important component of the treatment of metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potassium depletion with hypokalemia activates a collecting tubule H-K-ATPase that reabsorbs potassium in exchange for secreted hydrogen, which will increase bicarbonate reabsorption and maintain the alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/15\">",
"     15",
"    </a>",
"    ]. Correction of hypokalemia will decrease the activity of this cation exchanger, allowing bicarbonate to be excreted in the urine.",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    replacement restores the large intracellular potassium deficit that accompanies hypokalemia in metabolic alkalosis. The movement of administered potassium into cells occurs, in part, in exchange for intracellular hydrogen ions to maintain electroneutrality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/14\">",
"     14",
"    </a>",
"    ]. The movement of hydrogen ions out of cells and the repletion of intracellular potassium have several important effects, each of which will lower the plasma bicarbonate concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extracellular hydrogen ions buffer extracellular bicarbonate.",
"     </li>",
"     <li>",
"      In renal tubular cells, the reduction in intracellular hydrogen concentration raises the intracellular pH, which reduces hydrogen ion secretion and therefore bicarbonate reabsorption [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of potassium salts to correct hypokalemia is discussed in detail elsewhere. When potassium salts are administered to patients with metabolic alkalosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    <strong>",
"     is the preferred preparation",
"    </strong>",
"    . Potassium salts with organic anions, such as citrate or acetate, should be",
"    <strong>",
"     avoided",
"    </strong>",
"    if possible since metabolism of these anions generates bicarbonate, which will slow the rate of correction of the metabolic alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3820784#H3820784\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Potassium preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual dose of potassium is 10 to 20 meq given two to four times per day (20 to 80",
"    <span class=\"nowrap\">",
"     meq/day),",
"    </span>",
"    depending upon the severity of the hypokalemia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     Potassium chloride",
"    </a>",
"    can be given intravenously in patients who are unable to take oral medications or as an adjunct to oral therapy in patients who have severe or symptomatic hypokalemia. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3820392#H3820392\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Mild to moderate hypokalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3820210#H3820210\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Severe or symptomatic hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9857818\">",
"    <span class=\"h2\">",
"     Treatment of posthypercapnic metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic respiratory acidosis, which is most often due to chronic obstructive pulmonary disease, is initially associated with increased renal acid excretion and later with increased bicarbonate reabsorption. This results in a compensatory increase in the serum bicarbonate concentration that minimizes the fall in arterial pH (",
"    <a class=\"graphic graphic_figure graphicRef63315 \" href=\"UTD.htm?30/38/31341\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link&amp;anchor=H12584090#H12584090\">",
"     \"Simple and mixed acid-base disorders\", section on 'Respiratory acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the chronic respiratory acidosis improves as a result of mechanical ventilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical intervention, a posthypercapnic metabolic alkalosis may develop. In many cases, the patients cannot spontaneously excrete all of the excess bicarbonate because of a combination of chloride depletion, a reduction in the EABV (due, for example, to diuretic therapy or cor pulmonale),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reduction in glomerular filtration rate. Treatment of posthypercapnic metabolic alkalosis may be important since the metabolic alkalosis can reversibly worsen ventilation, exacerbate respiratory acidosis, and retard weaning from artificial ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of metabolic alkalosis\", section on 'Posthypercapnic alkalosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Posthypercapnic metabolic alkalosis can sometimes be corrected with isotonic saline, which corrects both chloride depletion and volume contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of metabolic alkalosis\", section on 'Posthypercapnic alkalosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1864673\">",
"     'Chloride depletion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the patient requires diuresis, then posthypercapnic metabolic alkalosis can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    . This increases urinary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    (and potassium) excretion. Initial studies suggested that acetazolamide also improves the respiratory acidosis as manifested by a fall in arterial PCO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, in a later study, acetazolamide reversed the metabolic alkalosis but did",
"    <strong>",
"     not",
"    </strong>",
"    improve the arterial PCO2 or accelerate weaning from the respirator [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When used in patients with posthypercapnic metabolic alkalosis, carbonic anhydrase inhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    can cause a small and transient rise in the arterial PCO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. This effect, which is not clinically significant in most patients, is due to inhibition of carbonic anhydrase in red blood cells which slows CO2 transport from red blood cells to the alveolar space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9857825\">",
"    <span class=\"h2\">",
"     Dialysis and hydrochloric acid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients with metabolic alkalosis do not adequately respond to, or are not candidates for, conventional therapies (volume expansion, chloride repletion, and potassium repletion) or therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    . One example is metabolic alkalosis developing in patients with advanced acute or chronic kidney disease in whom therapies aimed at increasing urinary bicarbonate excretion are less likely to be effective. In some cases, dialysis will be indicated. Dialysis with a low bicarbonate bath concentration will rapidly improve the alkalosis. However, current dialysis equipment makes it difficult to manipulate the bicarbonate bath concentrations to such low levels. Because the patient's bicarbonate in such cases is usually higher than a standard dialysis bicarbonate bath concentration, dialysis should nonetheless improve the metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe metabolic alkalosis (for example, HCO3 greater than 50",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pH greater than 7.55) who have renal insufficiency and cannot, or should not, be dialyzed can be treated with an intravenous infusion of hydrochloric acid (HCl) or an HCl precursor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"     ammonium chloride",
"    </a>",
"    , which is metabolized to urea and HCl.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22245432\">",
"    <span class=\"h3\">",
"     Hydrochloric acid regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCl for infusion is prepared by passing 100 or 150 mL of 1 normal (1 N) HCl through a 22 &micro;m filter into 800 or 850 mL of 5 percent dextrose, isotonic saline, or sterile water to produce a 0.1 N or 0.15 N solution of HCl [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/22\">",
"     22",
"    </a>",
"    ]. This solution must then be infused through a carefully placed, free flowing central venous catheter into the superior vena cava over 8 to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Because HCl may react with plastic, use of glass containers is recommended, and intravenous tubing should be changed every 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/22\">",
"     22",
"    </a>",
"    ]. Caution is required because infiltration of this solution will necrose tissues and can lead to death [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, HCl was mixed with an amino acid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/29/17878?source=see_link\">",
"     fat emulsion",
"    </a>",
"    solution, which buffers the pH to the degree that it can safely be infused into a peripheral vein [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"     Ammonium chloride",
"    </a>",
"    (NH4Cl) is available in 20 mL vials that contain 100 meq of NH4Cl. One or two vials are added to 1000 mL of isotonic saline [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, the ammonium is metabolized to urea, and the urea concentration can increase sharply in patients with renal insufficiency. High ammonia levels are also possible and can produce central nervous system manifestations, especially in patients with liver disease.",
"   </p>",
"   <p>",
"    Arginine hydrochloride, which is approved for use in the United States as a diagnostic infusion to test pituitary function, has been used in the past to treat metabolic alkalosis. However, it is not approved in the United States for this indication, and we do not recommend that it be used to treat metabolic alkalosis because it can cause potassium to shift from cells into the extracellular space, resulting in life-threatening hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14568/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rough estimate of the amount of acid or acid precursor (in meq) that will be required to reduce the plasma bicarbonate to the normal value of approximately 24",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    can be determined by multiplying the desired change in plasma bicarbonate concentration by the space of distribution of bicarbonate, which is roughly equal to the total body water (approximately 60 and 50 percent of lean body weight [LBW] in men and women, respectively).",
"   </p>",
"   <p>",
"    Thus, in men:",
"   </p>",
"   <p>",
"    &nbsp;HCO3 excess (in meq) &nbsp;= &nbsp;0.6 &nbsp;x &nbsp;LBW &nbsp;x &nbsp;(plasma HCO3 &nbsp;minus 24)",
"   </p>",
"   <p>",
"    In women:",
"   </p>",
"   <p>",
"    &nbsp;HCO3 excess (in meq) &nbsp;= &nbsp;0.5 &nbsp;x &nbsp;LBW &nbsp;x &nbsp;(plasma HCO3 minus 24)",
"   </p>",
"   <p>",
"    As an example, in a woman with an LBW of 60 kg and a plasma bicarbonate concentration of 38",
"    <span class=\"nowrap\">",
"     meq/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;HCO3 excess &nbsp;= &nbsp;0.5 &nbsp;x &nbsp;60 &nbsp;x &nbsp;14 &nbsp;= &nbsp;420 meq",
"   </p>",
"   <p>",
"    It is essential to appreciate that that this formula is a",
"    <strong>",
"     rough estimate",
"    </strong>",
"    that only estimates LBW and does",
"    <strong>",
"     not",
"    </strong>",
"    take into account continuing acid losses (as with nasogastric suction) or changes in the patient's volume status or potassium balance or renal function. In addition, only enough acid or acid precursor should be infused to partially correct the alkalosis, and then the patient should be reassessed. Thus, in these rare instances in which acid therapy is used, we only infuse one liter of solution (containing 100 meq of HCL or NH4CL) at a time, even if the estimated amount of acid required is higher than 100 meq. We then remeasure the serum chemistries to determine if additional acid therapy is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1865513\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two factors are required for the genesis and then maintenance of metabolic alkalosis: a process that raises the plasma bicarbonate concentration (",
"      <a class=\"graphic graphic_table graphicRef57489 \" href=\"UTD.htm?26/4/26699\">",
"       table 1",
"      </a>",
"      ), and a process that prevents excretion of the excess bicarbonate in the urine. (See",
"      <a class=\"local\" href=\"#H1039092\">",
"       'Overview of the pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of impaired renal bicarbonate excretion in patients with metabolic alkalosis are a reduction in the effective arterial blood volume (EABV, also called effective circulating volume), chloride depletion, hypokalemia, and acute and chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H9319118\">",
"       'Factors that impair bicarbonate excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of metabolic alkalosis should be aimed at reversing the etiology of bicarbonate generation and reversing the factors which prevent the excretion of the excess bicarbonate. In order to accomplish this, two questions must be answered (see",
"      <a class=\"local\" href=\"#H9857754\">",
"       'Treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Is the increase in plasma bicarbonate concentration due to an exogenous alkali load, gastrointestinal or renal hydrogen ion loss (eg, vomiting, diuretic therapy) with or without contraction alkalosis, an intracellular shift of hydrogen ions, or a combination of these disorders (",
"      <a class=\"graphic graphic_table graphicRef57489 \" href=\"UTD.htm?26/4/26699\">",
"       table 1",
"      </a>",
"      )?",
"     </li>",
"     <li>",
"      Why is the excess bicarbonate not being excreted in the urine?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The underlying etiology of the alkalosis should be reversed (eg, treating the cause of vomiting, stopping or slowing the removal of gastric secretions and reducing the acidity of these secretions, and stopping loop or thiazide diuretics). Any exogenous sources of alkali should be discontinued. Hypokalemia, which is often present, should be corrected. (See",
"      <a class=\"local\" href=\"#H1863594\">",
"       'Treat the underlying cause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintenance of metabolic alkalosis is due to a reduction in the renal excretion of the excess bicarbonate. The reversal of metabolic alkalosis requires the renal excretion of bicarbonate whenever possible. (See",
"      <a class=\"local\" href=\"#H1863671\">",
"       'Enhance renal bicarbonate excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduced EABV and chloride depletion usually occur together, and the treatment of EABV depletion with isotonic saline (sodium chloride) simultaneously corrects the volume and chloride deficits and generally increases renal bicarbonate excretion in patients with true volume depletion. However, isotonic saline is not indicated when the EABV depletion is caused by heart failure or cirrhosis. (See",
"      <a class=\"local\" href=\"#H1863706\">",
"       'Reduced effective arterial blood volume and chloride depletion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1864356\">",
"       'True volume depletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When metabolic alkalosis develops in patients with reduced EABV due to conditions such as heart failure or cirrhosis, treatment includes the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a potassium-sparing diuretic or, uncommonly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      if further diuresis is required. (See",
"      <a class=\"local\" href=\"#H1864600\">",
"       'Edematous states'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypokalemia in patients with metabolic alkalosis represents a large intracellular potassium deficit. The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      corrects both the potassium deficit and helps reverse the metabolic alkalosis. (See",
"      <a class=\"local\" href=\"#H9857783\">",
"       'Potassium depletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic respiratory acidosis, which is most often due to chronic obstructive pulmonary disease, is initially associated with increased renal acid excretion and later with increased bicarbonate reabsorption. This produces a compensatory increase in the serum bicarbonate concentration that minimizes the fall in arterial pH (",
"      <a class=\"graphic graphic_figure graphicRef63315 \" href=\"UTD.htm?30/38/31341\">",
"       figure 2",
"      </a>",
"      ). If the chronic respiratory acidosis improves as a result of mechanical ventilation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      medical intervention, a posthypercapnic metabolic alkalosis may develop. Many patients with posthypercapnic metabolic alkalosis can be effectively treated with isotonic saline infusion, which corrects EABV and chloride deficits. Another option for the treatment of posthypercapnic metabolic alkalosis is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      , which increases urinary bicarbonate excretion. (See",
"      <a class=\"local\" href=\"#H9857818\">",
"       'Treatment of posthypercapnic metabolic alkalosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uncommonly, patients with metabolic alkalosis do not adequately respond to, or are not candidates for, conventional therapies (volume expansion, chloride repletion, and potassium repletion) or therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      . One example is metabolic alkalosis developing in patients with advanced acute or chronic kidney disease. Such patients can often be treated with dialysis. (See",
"      <a class=\"local\" href=\"#H9857825\">",
"       'Dialysis and hydrochloric acid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, patients with severe metabolic alkalosis (eg, HCO3 greater than 50",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pH greater than 7.55) fail or are not candidates for conventional therapies and cannot, or should not, be dialyzed. Such patients can be treated with an intravenous infusion of hydrochloric acid (HCl) or an HCl precursor such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"       ammonium chloride",
"      </a>",
"      , which is metabolized to urea and HCl. (See",
"      <a class=\"local\" href=\"#H9857825\">",
"       'Dialysis and hydrochloric acid therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.552.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/2\">",
"      Schwartz WB, Kassirer JP. Role of anions in metabolic alkalosis and potassium deficiency. N Engl J Med 1968; 279:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/3\">",
"      VAN GOIDSENHOVEN GM, GRAY OV, PRICE AV, SANDERSON PH. The effect of prolonged administration of large doses of sodium bicarbonate in man. Clin Sci (Lond) 1954; 13:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/4\">",
"      Galla JH. Metabolic alkalosis. J Am Soc Nephrol 2000; 11:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/5\">",
"      Barton CH, Vaziri ND, Ness RL, et al. Cimetidine in the management of metabolic alkalosis induced by nasogastric drainage. Arch Surg 1979; 114:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/6\">",
"      Kirsch BM, Sunder-Plassmann G, Schwarz C. Metabolic alkalosis in a hemodialysis patient--successful treatment with a proton pump inhibitor. Clin Nephrol 2006; 66:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/7\">",
"      Luke RG, Galla JH. It is chloride depletion alkalosis, not contraction alkalosis. J Am Soc Nephrol 2012; 23:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/8\">",
"      Galla JH, Gifford JD, Luke RG, Rome L. Adaptations to chloride-depletion alkalosis. Am J Physiol 1991; 261:R771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/9\">",
"      Verlander JW, Madsen KM, Galla JH, et al. Response of intercalated cells to chloride depletion metabolic alkalosis. Am J Physiol 1992; 262:F309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/10\">",
"      Wagner CA, Devuyst O, Bourgeois S, Mohebbi N. Regulated acid-base transport in the collecting duct. Pflugers Arch 2009; 458:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/11\">",
"      SCHWARTZ WB, HAYS RM, POLAK A, HAYNIE GD. Effects of chronic hypercapnia on electrolyte and acid-base equilibrium. II. Recovery, with special reference to the influence of chloride intake. J Clin Invest 1961; 40:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/12\">",
"      Wall BM, Byrum GV, Galla JH, Luke RG. Importance of chloride for the correction of chronic metabolic alkalosis in the rat. Am J Physiol 1987; 253:F1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/13\">",
"      Tannen RL, Bleich HL, Schwartz WB. The renal response to acid loads in metabolic alkalosis; an assessment of the mechanisms regulating acid excretion. J Clin Invest 1966; 45:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/14\">",
"      COOKE RE, SEGAR WE, CHEEK DB, et al. The extrarenal correction of alkalosis associated with potassium deficiency. J Clin Invest 1952; 31:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/15\">",
"      Eiam-Ong S, Kurtzman NA, Sabatini S. Regulation of collecting tubule adenosine triphosphatases by aldosterone and potassium. J Clin Invest 1993; 91:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/16\">",
"      Capasso G, Jaeger P, Giebisch G, et al. Renal bicarbonate reabsorption in the rat. II. Distal tubule load dependence and effect of hypokalemia. J Clin Invest 1987; 80:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/17\">",
"      Bear R, Goldstein M, Phillipson E, et al. Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. Can Med Assoc J 1977; 117:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/18\">",
"      Miller PD, Berns AS. Acute metabolic alkalosis perpetuating hypercarbia. A role for acetazolamide in chronic obstructive pulmonary disease. JAMA 1977; 238:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/19\">",
"      Faisy C, Mokline A, Sanchez O, et al. Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation. Intensive Care Med 2010; 36:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/20\">",
"      Taki K, Mizuno K, Takahashi N, Wakusawa R. Disturbance of CO2 elimination in the lungs by carbonic anhydrase inhibition. Jpn J Physiol 1986; 36:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/21\">",
"      Taki K, Mizuno K, Takahashi N, Wakusawa R. Disturbance of CO2 elimination in the lungs by carbonic anhydrase inhibition. Jpn J Physiol 1986; 36:523.",
"     </a>",
"    </li>",
"    <li>",
"     Frick PG, Senning A. The treatment of severe metabolic alkalosis with intravenous N /10 or N /5 hydrochloric acid. Germ Med Monthly 1964; 9:242",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/23\">",
"      Wagner CW, Nesbit RR Jr, Mansberger AR Jr. Treatment of metabolic alkalosis with intravenous hydrochloric acid. South Med J 1979; 72:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/24\">",
"      Kwun KB, Boucherit T, Wong J, et al. Treatment of metabolic alkalosis with intravenous infusion of concentrated hydrochloric acid. Am J Surg 1983; 146:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/25\">",
"      Buchanan IB, Campbell BT, Peck MD, Cairns BA. Chest wall necrosis and death secondary to hydrochloric acid infusion for metabolic alkalosis. South Med J 2005; 98:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/26\">",
"      Knutsen OH. New method for administration of hydrochloric acid in metabolic alkalosis. Lancet 1983; 1:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/27\">",
"      Martin WJ, Matzke GR. Treating severe metabolic alkalosis. Clin Pharm 1982; 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/28\">",
"      Warren SE, Swerdlin AR, Steinberg SM. Treatment of alkalosis with ammonium chloride: a case report. Clin Pharmacol Ther 1979; 25:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14568/abstract/29\">",
"      Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med 1978; 89:632.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2345 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14568=[""].join("\n");
var outline_f14_14_14568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1865513\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9857747\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1039092\">",
"      OVERVIEW OF THE PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9319111\">",
"      Factors that increase plasma bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9319118\">",
"      Factors that impair bicarbonate excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9857754\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1863594\">",
"      Treat the underlying cause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1863671\">",
"      Enhance renal bicarbonate excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1863706\">",
"      - Reduced effective arterial blood volume and chloride depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1864356\">",
"      True volume depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1864600\">",
"      Edematous states",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1864673\">",
"      Chloride depletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9857783\">",
"      - Potassium depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9857818\">",
"      Treatment of posthypercapnic metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9857825\">",
"      Dialysis and hydrochloric acid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22245432\">",
"      - Hydrochloric acid regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1865513\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2345\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2345|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/31/17917\" title=\"figure 1\">",
"      Distal HCO3 secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/38/31341\" title=\"figure 2\">",
"      Chronic respiratory acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2345|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/4/26699\" title=\"table 1\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=related_link\">",
"      Acetazolamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=related_link\">",
"      Clinical manifestations and evaluation of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30503?source=related_link\">",
"      General principles of the treatment of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39128?source=related_link\">",
"      Mechanism of action of diuretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_14_14569="Initial management of distal forearm fractures in children";
var content_f14_14_14569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial management of distal forearm fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14569/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14569/contributors\">",
"     Paula Schweich, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14569/contributors\">",
"     Jennifer Wang, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14569/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14569/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/14/14569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2137856\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood forearm fractures are very common and typically occur after a fall on an outstretched hand. Early assessment should focus on identifying an open fracture, neurovascular compromise,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated injuries. The correct radiographic diagnosis at the time of injury is essential to proper care.",
"   </p>",
"   <p>",
"    Initial care of nondisplaced fractures consists of pain control, splinting, and measures aimed at reducing swelling. Nondisplaced distal forearm fractures other than complete fractures of the distal radius and ulna can then be referred for scheduled evaluation and further management by an orthopedist with pediatric expertise.",
"   </p>",
"   <p>",
"    Closed reduction is adequate treatment for many displaced forearm fractures and is often accomplished under sedation in the emergency department. Prompt orthopedic consultation is indicated for an important subset of distal forearm fractures to ensure the best outcome. Early orthopedic follow-up for potentially unstable fractures is essential to avoid long-term complications.",
"   </p>",
"   <p>",
"    The initial management of distal forearm fractures in children will be reviewed here. The diagnosis, assessment, fracture reduction, and casting of distal forearm fractures in children and the care of pediatric proximal or midshaft forearm fractures are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=see_link\">",
"       \"Diagnosis and assessment of distal forearm fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link\">",
"       \"Closed reduction and casting of distal forearm fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11609?source=see_link\">",
"       \"Midshaft forearm fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3546?source=see_link\">",
"       \"Proximal fractures of the forearm in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals for initial care of children with a suspected distal forearm fractures are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify and treat vascular compromise",
"     </li>",
"     <li>",
"      Identify open fractures &nbsp;",
"     </li>",
"     <li>",
"      Provide analgesia and immobilization",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Absent pulse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency clinician should promptly identify children with vascular insufficiency and emergently involve an orthopedic surgeon with appropriate pediatric expertise. Rarely, these children may require partial closed reduction in the emergency department in an attempt to restore distal circulation. Patients who display a cold, white, or cyanotic hand despite reduction attempts require operative exploration and vascular repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2139229\">",
"    <span class=\"h2\">",
"     Open fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with open fractures of the distal forearm should receive the following initial care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Application of a sterile dressing",
"     </li>",
"     <li>",
"      Tetanus prophylaxis, as needed (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intravenous antibiotics directed at the most common organisms (",
"      <em>",
"       Staphylococcus",
"      </em>",
"      <em>",
"       aureus",
"      </em>",
"      , coagulase-negative staphylococci, and aerobic Gram negative bacilli). For children at low risk of methicillin-resistant",
"      <em>",
"       Staphylococcus",
"      </em>",
"      <em>",
"       aureus",
"      </em>",
"      (MRSA),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"       cefuroxime",
"      </a>",
"      alone or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"       cefazolin",
"      </a>",
"      with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      provide adequate coverage.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      should be added for patients with risk factors for MRSA (eg, recent MRSA infection, family members with MRSA infection, diabetes mellitus). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment and prevention of osteomyelitis following trauma\", section on 'Prophylactic antibiotics'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Predebridement wound cultures do",
"    <strong>",
"     not",
"    </strong>",
"    correlate with infectious pathogens in patients with open fractures and are",
"    <strong>",
"     not",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Analgesia and immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with no signs of vascular compromise, initial therapy consists of pain management and immobilization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral analgesia (eg, intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      0.1 to 0.15",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose: 10 mg) is most appropriate for initial pain control in patients with moderate to severe pain and should be given prior to radiographic evaluation.",
"     </li>",
"     <li>",
"      Oral analgesia (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      may suffice for patients who have suffered a nondisplaced forearm fracture, especially a torus (buckle) fracture. In most circumstances, pain relief will result in an improved ability to assess neurovascular status in the apprehensive child. Oral medications should be avoided in patients in whom reduction under sedation or general anesthesia are anticipated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with significant deformity, immobilizing the injured arm prior to taking radiographs promotes pain relief and avoids additional soft tissue injury from inadvertent arm movement. In this situation, the arm should be splinted \"as it lies\" (typically a sugar tong splint using prefabricated splinting material or eight layers of plaster with under cast padding (eg, Webril&reg;) and loosely applied elastic bandages (eg, Ace&reg; wrap)) (",
"    <a class=\"graphic graphic_figure graphicRef50501 \" href=\"UTD.htm?36/26/37281\">",
"     figure 1",
"    </a>",
"    ). Neurovascular status should be checked before and after splinting. If any further compromise is found after immobilization, then the splinting material should be removed and the arm position should be adjusted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H12#H12\">",
"     \"Splinting of musculoskeletal injuries\", section on 'Sugar tong splints'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients without obvious deformity may be initially managed with a splint and sling or a sling alone for additional pain relief during radiographic assessment.",
"   </p>",
"   <p>",
"    After immobilization, patients",
"    <strong>",
"     without",
"    </strong>",
"    vascular compromise should elevate the distal forearm above the level of the heart and should have a cold pack applied while awaiting definitive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt orthopedic consultation should be obtained for children with any of the following distal forearm fractures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open fractures",
"     </li>",
"     <li>",
"      Fractures with neurovascular compromise",
"     </li>",
"     <li>",
"      Salter III, IV, or V physeal fractures (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76017 \" href=\"UTD.htm?31/58/32672\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61682 \" href=\"UTD.htm?31/18/32035\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Single displaced radius fractures with intact ulna where a difficult reduction is anticipated",
"     </li>",
"     <li>",
"      Forearm fractures complicated by wrist or elbow dislocation or supracondylar fracture",
"     </li>",
"     <li>",
"      Displaced Salter I or II physeal fractures (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79636 \" href=\"UTD.htm?13/48/14080\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Angulated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complete fractures (if the clinician is not experienced in fracture reduction, splinting or casting) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67542 \" href=\"UTD.htm?26/59/27583\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Galeazzi fractures (oblique or transverse radial fracture with dislocation of the distal ulna)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence suggests that clinicians who are experienced in pediatric fracture reduction and cast or splint immobilization of the reduced fracture can provide this care for displaced Salter I or II, greenstick, or complete distal forearm fractures with good outcomes. As an example, fractures reduced and casted by trained pediatric emergency physicians had a similar healing, shorter emergency department stays, lower facility charges, and no increased short-term cast problems when compared to reduction by orthopedist residents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DEFINITIVE CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Physeal fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the growth plate may be apparent on plain radiographs or, in patients with nondisplaced Salter I fractures, inferred by localized tenderness over the physis. The type of fracture, based upon the Salter-Harris classification (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"     figure 2",
"    </a>",
"    ) and the degree of displacement determine the treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=see_link&amp;anchor=H730724#H730724\">",
"     \"Diagnosis and assessment of distal forearm fractures in children\", section on 'Physeal fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Nondisplaced Salter I or II fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nondisplaced Salter I or II fractures should receive immobilization with a sling and a short arm splint or short arm cast for three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4\">",
"     4",
"    </a>",
"    ]. A volar splint is typically adequate for a Salter I fracture while a sugar tong splint is advisable for a Salter II fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H8#H8\">",
"     \"Splinting of musculoskeletal injuries\", section on 'Upper extremity splints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136787#H2136787\">",
"     \"Closed reduction and casting of distal forearm fractures in children\", section on 'Immobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Follow-up with an orthopedic surgeon with appropriate pediatric expertise should occur within seven days. Nondisplaced Salter I or II fractures typically require immobilization with a splint or cast for three to four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Displaced Salter I or II fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of these fractures focuses on reducing the fracture and maintaining arm support during the healing period. The reduction should be performed as soon as possible (within a week), as the growth plate heals quickly and closed reduction after seven days is associated with injury to the growth plate and a higher risk of growth arrest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79636 \" href=\"UTD.htm?13/48/14080\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57356 \" href=\"UTD.htm?19/52/20290\">",
"     image 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136780#H2136780\">",
"     \"Closed reduction and casting of distal forearm fractures in children\", section on 'Salter I or II fracture reduction'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H43\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Follow-up with an orthopedic surgeon with appropriate pediatric expertise should occur within seven days. Displaced Salter I or II fractures typically require immobilization with a splint or cast for three to four weeks. Since these fractures do not involve the joint, they have an excellent prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Salter III, IV, and V fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;These fractures warrant prompt consultation with an orthopedist with appropriate pediatric expertise. Salter type III fractures involve the joint surface (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76017 \" href=\"UTD.htm?31/58/32672\">",
"     image 1",
"    </a>",
"    ). They commonly need open reduction to obtain a stable joint.",
"   </p>",
"   <p>",
"    Salter type IV and V fractures also typically require open reduction with internal fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/6\">",
"     6",
"    </a>",
"    ]. Salter IV fractures are unstable, and perfect reduction is necessary for a good outcome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61682 \" href=\"UTD.htm?31/18/32035\">",
"     image 2",
"    </a>",
"    ). These fractures usually heal in four to six weeks. Salter type V fractures are frequently difficult to identify at initial evaluation and are followed by premature growth plate closure and growth arrest several months later. (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After healing, follow-up for all growth plate fractures is recommended at four to six months and again at a year, in order to detect any growth arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. If the radial growth plate closes and the ulna continues to grow, a wrist deformity will occur (",
"    <a class=\"graphic graphic_picture graphicRef81435 \" href=\"UTD.htm?4/19/4401\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Torus (buckle) fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A buckle fracture occurs at the distal metaphysis, where the bone is most porous, usually in younger children (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67725 \" href=\"UTD.htm?38/52/39744\">",
"     image 6",
"    </a>",
"    ). This injury is caused by buckling of the cortex due to compression failure. Torus fractures are stable, and treatment is aimed at pain relief, comfort, and protection of the bone from any further injury using a short arm cast or a splint (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67725 \" href=\"UTD.htm?38/52/39744\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81117 \" href=\"UTD.htm?26/56/27520\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=see_link&amp;anchor=H730731#H730731\">",
"     \"Diagnosis and assessment of distal forearm fractures in children\", section on 'Torus (buckle) fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on several small trials, we suggest that children with a torus (buckle) fracture receive a removable splint for immobilization rather than a below-elbow cast [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. However, the choice of splint versus cast is dependent on the degree of initial pain, the degree of anticipated activity of the child, and parental preference. A splint can be removed for showering and minor activities, and may be preferable by some caregivers, but a cast offers more protection of the fracture site in active children.",
"   </p>",
"   <p>",
"    Before treating with a splint, it is crucial to radiographically distinguish a buckle fracture from a nondisplaced greenstick fracture. Patients with greenstick fractures warrant casting as volar splints may not prevent refracture during healing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Greenstick fracture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Current evidence does not identify the optimal type of removable splint (eg, premolded splint versus molded volar plaster or fiberglass splint). In the authors&rsquo; experience, a well-padded, molded volar splint (either plaster or fiberglass) is easy to apply and comfortable.",
"   </p>",
"   <p>",
"    A meta-analysis found four trials (3 randomized and 1 quasi-randomized) that compared below-elbow casting with various forms of removable splinting materials (eg, premolded splint, soft bandage, molded plaster splint) for the treatment of torus fractures in 417 children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/8\">",
"     8",
"    </a>",
"    ]. In all trials, no short-term deformity occurred regardless of treatment. Two of the four trials in this meta-analysis provide data on frequency of refracture, impact of care on activities, parenteral preference, and pain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of 201 children reported no episodes of refracture (113 splinted fractures and 85 casted fractures) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trial of 87 children treated in a children's hospital compared the impact of molded plaster splints versus short arm casts on the self-reported time it took to return to normal activities [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/11\">",
"       11",
"      </a>",
"      ]. Children who were splinted achieved close to normal functioning with negligible pain at 14 days, although they reported mild pain more frequently at day seven than casted children. Casted children still had mild disability at 14 days. More parents indicated that they preferred the treatment their child received in the splint group",
"      <span class=\"nowrap\">",
"       (17/20,",
"      </span>",
"      85 percent) than in the cast group",
"      <span class=\"nowrap\">",
"       (13/25,",
"      </span>",
"      52 percent). No refractures occurred in the 75 children for whom six month phone follow-up was available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another small trial of 84 children treated in a children's hospital found that there was an increased duration of pain in children who received a fiberglass molded splint versus a cast (median six versus three days, p&lt;0.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/9\">",
"     9",
"    </a>",
"    ]. However, splinted patients had increased baseline pain and were more likely to have a radial torus fracture.",
"   </p>",
"   <p>",
"    Taken together, the evidence suggests that children with buckle fractures may be safely treated with a removable splint and that a splint may encourage earlier return to normal activities than a short arm cast. Splinting may initially be more painful than casting and may not be ideal in children with higher baseline pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up for a torus (buckle) fracture depends upon the treatment provided:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with splints may remove them at home after three weeks",
"      <strong>",
"       without",
"      </strong>",
"      orthopedic follow-up. These fractures do not displace during healing [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/13\">",
"       13",
"      </a>",
"      ]. Thus, additional radiographs are unnecessary [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/8,14,15\">",
"       8,14,15",
"      </a>",
"      ]. Orthopedic evaluation should occur for children with torus fractures and bowing of the arm, diminished range of motion, continued pain, or parental concerns [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/8,14,16-18\">",
"       8,14,16-18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Despite this recommended time for splint immobilization, an observational study of 39 children with buckle fractures found that children often stop using their splints after two weeks with no negative consequences [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/18\">",
"       18",
"      </a>",
"      ]. In another study, a soft bandage was used in 14 children, and most had removed the bandage by one week's time, allowing more comfort and early range of motion [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/17\">",
"       17",
"      </a>",
"      ]. These findings suggest that the timing of splint immobilization may be modified depending upon the child's level of activity and degree of discomfort.",
"     </li>",
"     <li>",
"      If casted, buckle fractures should undergo cast removal in three weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Greenstick fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with greenstick fractures have a complete fracture of the tension side of the cortex of the radius or ulna and a plastic deformation, or buckling, of the compression side (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80128 \" href=\"UTD.htm?29/44/30400\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69866 \" href=\"UTD.htm?31/45/32478\">",
"     image 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=see_link&amp;anchor=H730738#H730738\">",
"     \"Diagnosis and assessment of distal forearm fractures in children\", section on 'Greenstick fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients typically require immobilization in a long arm cast for three to four weeks followed by short arm casting for an additional two to three weeks (six weeks total casting) depending upon the speed of radiographic healing. These patients should see an orthopedist on a regular basis while casted. Unlike buckle fractures, greenstick fractures are unstable and may continue to displace after casting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Nondisplaced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with nondisplaced greenstick fractures should undergo splinting with reevaluation and casting by an orthopedic surgeon in three to five days. Experienced clinicians may choose to apply a long arm cast in the emergency department (",
"    <a class=\"graphic graphic_figure graphicRef52462 \" href=\"UTD.htm?15/46/16096\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136787#H2136787\">",
"     \"Closed reduction and casting of distal forearm fractures in children\", section on 'Immobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Mild displacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some angulated or displaced greenstick fractures can be splinted without reduction and undergo reevaluation in three to five days by an orthopedic surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. The degree of angulation that is treated in this manner depends upon the patient's age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4\">",
"     4",
"    </a>",
"    ]. The actual angle should be measured with a goniometer or other tool, as estimations are often inaccurate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of angulation that can be treated",
"    <strong>",
"     without",
"    </strong>",
"    reduction by age is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children under 5 years of age",
"      </strong>",
"      &ndash; 10 to 35 degrees of angulation on lateral plain radiograph and up to 10 degrees of angulation on the AP view",
"     </li>",
"     <li>",
"      <strong>",
"       Children 5 to under 10 years of age",
"      </strong>",
"      &ndash; 10 to 25 degrees of angulation on lateral plain radiograph and up to 10 degrees of angulation on the AP view",
"     </li>",
"     <li>",
"      <strong>",
"       Children over 10 years of age",
"      </strong>",
"      &ndash; 5 to 20 degrees of angulation on lateral plain radiograph and 0 degrees of angulation on the AP view",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, these mildly angulated greenstick fractures can be casted without previous reduction, and then gently reduced while the cast materials are setting (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64466 \" href=\"UTD.htm?5/39/5745\">",
"     image 10",
"    </a>",
"    ). The reduction is held in place with a three-point smoothly molded cast (",
"    <a class=\"graphic graphic_figure graphicRef52462 \" href=\"UTD.htm?15/46/16096\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136787#H2136787\">",
"     \"Closed reduction and casting of distal forearm fractures in children\", section on 'Immobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When questions about the need for reduction arise in children with greenstick distal forearm fractures, discussion with an orthopedic surgeon is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Moderate to severe displacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt reduction by an experienced clinician or orthopedic surgeon is indicated for fractures with greater angulation than described above, or in cases where the arm looks angulated on visual inspection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Mild displacement'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136773#H2136773\">",
"     \"Closed reduction and casting of distal forearm fractures in children\", section on 'Greenstick fracture reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Complete fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fracture is considered complete when it passes through both cortices of the distal metaphysis (distal third) of the radius",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulna, often with displacement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67542 \" href=\"UTD.htm?26/59/27583\">",
"     image 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=see_link&amp;anchor=H730745#H730745\">",
"     \"Diagnosis and assessment of distal forearm fractures in children\", section on 'Complete fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of complete distal forearm fractures is highly dependent upon the age of the child; the involved area of the bone(s); and the degree of angulation, displacement, and malrotation. If a metaphyseal fracture is isolated to the distal radius, it is not uncommon for it to be nondisplaced (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53760 \" href=\"UTD.htm?19/33/19984\">",
"     image 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/20\">",
"     20",
"    </a>",
"    ]. When questions about the need for reduction arise in children with complete distal forearm fractures, discussion with an orthopedic surgeon is warranted.",
"   </p>",
"   <p>",
"    Management by type of fracture is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nondisplaced or minimally displaced metaphyseal fractures (one or both bones) have a great potential for remodeling because of the proximity to the distal growth plate. Nondisplaced isolated radial metaphyseal fractures with up to 15 to 20 degrees angulation can be splinted in a sugar tong splint or casted without reduction in children under 10 years of age (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53760 \" href=\"UTD.htm?19/33/19984\">",
"       image 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4,5,8,21\">",
"       4,5,8,21",
"      </a>",
"      ]. As an example, a trial of splinting versus casting of minimally displaced (5 mm or less) or minimally angulated (15 degrees or less) transverse fractures of the distal radius in 96 children between 5 and 12 years of age found that the use of a fabricated splint was as effective as a short arm cast in terms of physical function at six weeks with no refracture seen in either group [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Isolated distal radius diaphyseal fractures with minimal lateral shift (&lt;2 mm), dorsal angulation of less than 10 degrees, and shortening of &lt;2 mm minimal angulation or minimal displacement can be casted without reduction [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/23\">",
"       23",
"      </a>",
"      ]. Although some investigators have reported casting duration for as short as one week [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/24\">",
"       24",
"      </a>",
"      ], most orthopedists would cast for three weeks. Similarly, bayonet apposition will heal well with casting alone in children under 10 years old as long as there is no rotational deformity and no angulation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/1,8\">",
"       1,8",
"      </a>",
"      ]. Bayonet apposition does not limit rotation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136766#H2136766\">",
"       \"Closed reduction and casting of distal forearm fractures in children\", section on 'Complete fracture reduction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136787#H2136787\">",
"       \"Closed reduction and casting of distal forearm fractures in children\", section on 'Immobilization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Displaced fractures and those with greater than 20 degrees angulation require closed reduction (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81035 \" href=\"UTD.htm?0/15/240\">",
"       image 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77309 \" href=\"UTD.htm?11/3/11315\">",
"       image 13",
"      </a>",
"      ). If adequate closed reduction is not achieved or cannot be maintained, distal complete fractures may ultimately need operative treatment, particularly if the child is over 10 years of age (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56680 \" href=\"UTD.htm?36/11/37055\">",
"       image 14",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136766#H2136766\">",
"       \"Closed reduction and casting of distal forearm fractures in children\", section on 'Complete fracture reduction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All complete fractures warrant follow-up with an orthopedic surgeon with pediatric expertise within seven days after splinting or casting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140102\">",
"    <span class=\"h2\">",
"     Ulnar styloid fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;This distal avulsion fracture typically occurs at the ulnar attachment site of the triangular fibrocartilage complex (TFCC) or the ulnocarpal ligament in conjunction with a radial fracture. In most instances, fracture management based upon the type of radial fracture with one rare exception; a displaced fracture that occurs at the base of the ulnar styloid may indicate a disruption of the TFCC and may warrant surgical intervention (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57244 \" href=\"UTD.htm?8/0/8194\">",
"     image 15",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21531142\">",
"    <span class=\"h2\">",
"     Galeazzi fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Galeazzi fracture is a fracture of the distal third of the radius along with dislocation of the distal radioulnar joint or ulnar physeal separation (Galeazzi-equivalent fracture) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54885 \" href=\"UTD.htm?35/49/36627\">",
"     image 16",
"    </a>",
"    ). This injury typically occurs after a fall onto an outstretched hand, and is very rare in children. These fractures warrant urgent consultation with an orthopedic surgeon with pediatric expertise for closed reduction followed by casting (skeletally immature children) or internal fixation (skeletally mature adolescents) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     FRACTURE REDUCTION AND CASTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods for reduction and casting of distal forearm fractures in children are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link\">",
"     \"Closed reduction and casting of distal forearm fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     DISCHARGE AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial care, children with distal forearm fractures should follow-up with an orthopedic surgeon with pediatric expertise. Timing depends upon the type of fracture and treatment provided:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Torus (buckle) fractures",
"      </strong>",
"      &ndash; Three weeks if a cast is placed; not required in splinted patients",
"     </li>",
"     <li>",
"      <strong>",
"       Splinted or casted physeal fractures",
"      </strong>",
"      &ndash; Within one week",
"     </li>",
"     <li>",
"      <strong>",
"       Splinted greenstick or complete fractures",
"      </strong>",
"      &ndash; 3 to 5 days",
"     </li>",
"     <li>",
"      <strong>",
"       Casted greenstick or complete fractures",
"      </strong>",
"      &ndash; 7 to 10 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients should be provided with a sling and instructed to keep the fracture site elevated above the level of the heart as much as possible for the first 48 hours after injury.",
"   </p>",
"   <p>",
"    Caretakers and children who received a cast should be given detailed cast care instructions. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"     \"Patient information: Cast and splint care (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who have received operative care should be admitted for 24 to 48 hour observation of neurovascular status and soft tissue compartments. Once discharged, these patients are followed closely and may require weekly orthopedic evaluation with radiographs to determine the optimal timing for subsequent hardware removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Home pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    should be used for initial pain management of reduced and immobilized distal forearm fractures. For example, a randomized trial of 336 children, between 4 and 18 years of age, with arm fractures found that children who initially received home pain therapy with oral ibuprofen were more likely to achieve adequate analgesia during the first three days after fracture reduction and immobilization than those who received",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32230?source=see_link\">",
"     codeine",
"    </a>",
"    (80 percent",
"    <span class=\"nowrap\">",
"     (102/128)",
"    </span>",
"    versus 69 percent",
"    <span class=\"nowrap\">",
"     (80/116);",
"    </span>",
"    95% CI for the difference -0.2 to 22.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients receiving ibuprofen also had significantly fewer adverse effects (30 versus 51 percent) with drowsiness, nausea, and vomiting comprising the adverse effects most prevalent in children receiving acetaminophen with codeine. The majority of children in this study had forearm fractures.",
"   </p>",
"   <p>",
"    Some clinicians may choose to provide a prescription for a limited amount of opioid pain medication (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=see_link\">",
"     oxycodone",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four hours; maximum 5 mg per dose for two to three days) to be used as a rescue medication in patients whose pain is not adequately controlled within one hour of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    administration. Opioid medication is especially appropriate for children who require fracture reduction at the initial visit.",
"   </p>",
"   <p>",
"    At 72 hours, continued pain requiring opioid analgesia is an indication for reevaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21531065\">",
"    <span class=\"h2\">",
"     Immobilization and return to activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper healing of displaced distal forearm fractures often require a long arm cast for four to six weeks followed by placement in a removable splint for an additional four to six weeks. High-risk activities (eg, skateboarding, all-terrain vehicle riding) should be restricted until solid radiographic union is achieved in order to reduce the chance of a refracture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For torus (buckle) fractures, children typically are immobilized for two to four weeks in a splint without any sports. At that point, the child may participate in sports while wearing the splint if allowable (eg, soccer) for two more weeks or until the forearm is fully recovered. If the child cannot wear the splint during sports, then he or she should refrain from team sports until the wrist is back to full function without pain (typically a total of four to six weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for full healing and recovery of arm function following distal forearm fractures is very good with proper diagnosis and treatment, especially in children with nondisplaced Salter I or II distal physeal fractures or torus (buckle) fractures.",
"   </p>",
"   <p>",
"    Close follow-up with an orthopedic surgeon is necessary for those fractures that are prone to growth arrest (eg, Salter III, IV, and V fractures and displaced Salter fractures), refracture (greenstick fractures and angulated complete fractures), or loss of reduction (complete fractures).",
"   </p>",
"   <p>",
"    Potential complications of distal forearm fractures vary depending upon the type of fracture:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Physeal fractures",
"      </strong>",
"      &ndash; Malunion represents the most common problem with these fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4\">",
"       4",
"      </a>",
"      ]. However, if the fracture occurs in a child with extensive growth remaining, then remodeling usually results in adequate healing and good wrist function. Because of the higher risk of damage to the growth plate with ensuing growth arrest, patients with displaced Salter I and II fractures require orthopedic referral within seven days of the injury [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4,29\">",
"       4,29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The risk of growth arrest increases significantly for Salter III, IV, or V fractures. Growth arrest in a skeletally immature child can lead to growth disparity between the radius and ulna that can cause ulnocarpal impaction syndrome (pain and clicking with wrist extension, ulnar deviation, or repetitive wrist loading), triangular fibrocartilage complex tear, and limitation of wrist motion and function (",
"      <a class=\"graphic graphic_picture graphicRef81435 \" href=\"UTD.htm?4/19/4401\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Median neuropathy may also occur after a radial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ulnar distal physeal fracture as a result of direct trauma or a secondary carpal tunnel syndrome. Fracture reduction or release of the carpal tunnel compression typically results in return of nerve function.",
"     </li>",
"     <li>",
"      <strong>",
"       Torus (buckle) fractures",
"      </strong>",
"      &ndash; Reinjury is the main complication of a torus fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/8,17\">",
"       8,17",
"      </a>",
"      ]. The lack of anatomic disruption makes neurovascular injury or long-term functional complications extremely unlikely.",
"     </li>",
"     <li>",
"      <strong>",
"       Greenstick fractures",
"      </strong>",
"      &mdash; Refracture occurs frequently in children with poorly healed greenstick fractures. For this reason, these fractures need to be adequately immobilized until radiographic and clinical healing are evident. In addition, activities should be restricted for additional time (one to six weeks) so that full recovery of arm movement and strength can occur [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H7#H7\">",
"       \"General principles of fracture management: Fracture patterns and description in children\", section on 'Greenstick'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Rarely, malunion or cross union between the radius and ulna may cause significant functional limitation.",
"     </li>",
"     <li>",
"      <strong>",
"       Complete fractures",
"      </strong>",
"      &ndash; Up to 25 percent of complete fractures displace during follow-up despite adequate initial closed reduction and casting [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/20\">",
"       20",
"      </a>",
"      ]. These fractures require repeat closed reduction or surgical intervention. In most instances, the deformity will remodel over time.",
"      <br/>",
"      <br/>",
"      Refracture is another common complication. Complete diaphyseal fractures are eight times more likely to refracture than complete metaphyseal fractures, with the rate of refracture highest in patients with the shortest duration of casting [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Adverse functional or cosmetic outcomes may also occur with forearm rotation being the motion most frequently affected [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/1,7\">",
"       1,7",
"      </a>",
"      ]. Poor outcomes are less common in younger children because of their extensive ability to remodel. For example, if the growth plates are open, about 50 percent of the remodeling will occur in the first six months. The remaining portion will occur in the next 18 months with no clinical deformity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/6\">",
"       6",
"      </a>",
"      ]. Typically, remodeling can correct about 10 degrees of apex-volar angulation for each year of growth remaining [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14569/abstract/5,30,31\">",
"       5,30,31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Growth arrest and neurovascular injuries may occur but are much less common than in patients with physeal fractures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The emergency clinician should promptly identify children with vascular insufficiency and emergently involve an orthopedic surgeon with appropriate pediatric expertise. Rarely, these children will require partial closed reduction in the emergency department in an attempt to restore distal circulation. Patients who display a cold, cyanotic or pale hand despite reduction attempts require emergent operative exploration and vascular repair. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Absent pulse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with adequate distal circulation, initial therapy consists of identification and initiation of care for open fractures, pain management and immobilization to prevent further displacement of the fracture. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Analgesia and immobilization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2139229\">",
"       'Open fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent orthopedic consultation is indicated for children with an open fracture, neurovascular compromise, forearm fracture complicated by joint dislocation, or supracondylar fracture. Prompt involvement of an orthopedic surgeon is appropriate for any patient with a displaced or angulated distal forearm fracture or Salter III, IV, or V fracture. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Definitive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some clinicians, who are experienced in fracture reduction and cast or splint immobilization of the reduced fracture, may choose to provide this care for displaced greenstick, complete, and displaced Salter I or II physeal fractures. Proper cast technique is essential to the overall success of the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link\">",
"       \"Closed reduction and casting of distal forearm fractures in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136787#H2136787\">",
"       \"Closed reduction and casting of distal forearm fractures in children\", section on 'Immobilization'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=see_link&amp;anchor=H2136759#H2136759\">",
"       \"Closed reduction and casting of distal forearm fractures in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with nondisplaced physeal, greenstick, or complete fractures may receive immobilization with a short arm splint or cast and a sling in the emergency department. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Physeal fracture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Greenstick fracture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Complete fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with a torus fracture receive a removable splint for immobilization rather than a below-elbow cast (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the choice of splint versus cast therapy depends on the degree of initial pain, the degree of anticipated activity of the child, and parental preference. Before placing a splint, the clinician should be certain that the child does not have a greenstick fracture. Children with splints may remove them at home after three weeks with orthopedic follow-up necessary only if there is bowing of the arm, diminished range of motion, continued pain or parental concerns. Children with casts may follow-up with an orthopedic surgeon in three weeks for cast removal. Further radiographs are unnecessary. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Torus (buckle) fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following definitive care, children with distal forearm fractures should follow-up with an orthopedic surgeon. Timing depends on the type of fracture and treatment provided. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Discharge and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis for full healing and recovery of arm function following distal forearm fractures is very good with proper diagnosis and treatment, especially in children with nondisplaced Salter I or II distal physeal fractures or torus (buckle) fractures. Close follow-up with an orthopedic surgeon is necessary for those fractures that are prone to growth arrest (eg, displaced Salter I and II fractures, Salter III, IV, and V fractures), refracture (greenstick fractures and angulated complete fractures), or loss of reduction (complete fractures). Long-term complications are rare. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Definitive care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H43\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/1\">",
"      Rodr&iacute;guez-Merch&aacute;n EC. Pediatric fractures of the forearm. Clin Orthop Relat Res 2005; :65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/2\">",
"      Zalavras CG, Patzakis MJ, Holtom PD, Sherman R. Management of open fractures. Infect Dis Clin North Am 2005; 19:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/3\">",
"      Khan S, Sawyer J, Pershad J. Closed reduction of distal forearm fractures by pediatric emergency physicians. Acad Emerg Med 2010; 17:1169.",
"     </a>",
"    </li>",
"    <li>",
"     Waters PM, Bae DS. Fractures of the distal radius and ulna. In: Rockwood and Wilkin's Fractures in Children, 7th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.292.",
"    </li>",
"    <li>",
"     Rang M, Stearns P, Chambers H. Radius and Ulna. In: Rang's Children's Fractures, 3rd, Rang M, Pring ME, Wenger DR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.135.",
"    </li>",
"    <li>",
"     Pizzutillo PD. Pediatric orthopaedics. In: Essentials of Musculoskeletal Care, 3rd, Griffin YL.  (Ed), American Academy of Orthopaedic Surgeons, Rosemont 2005. p.863.",
"    </li>",
"    <li>",
"     Price CT, Flynn JM. Management of fractures. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissey RT, Weinstein SL.  (Eds), Lippincott, Philadelphia 2006. p.1463.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/8\">",
"      Abraham A, Handoll HH, Khan T. Interventions for treating wrist fractures in children. Cochrane Database Syst Rev 2008; :CD004576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/9\">",
"      Oakley EA, Ooi KS, Barnett PL. A randomized controlled trial of 2 methods of immobilizing torus fractures of the distal forearm. Pediatr Emerg Care 2008; 24:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/10\">",
"      Davidson JS, Brown DJ, Barnes SN, Bruce CE. Simple treatment for torus fractures of the distal radius. J Bone Joint Surg Br 2001; 83:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/11\">",
"      Plint AC, Perry JJ, Correll R, et al. A randomized, controlled trial of removable splinting versus casting for wrist buckle fractures in children. Pediatrics 2006; 117:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/12\">",
"      Kropman RH, Bemelman M, Segers MJ, Hammacher ER. Treatment of impacted greenstick forearm fractures in children using bandage or cast therapy: a prospective randomized trial. J Trauma 2010; 68:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/13\">",
"      Randsborg PH, Sivertsen EA. Distal radius fractures in children: substantial difference in stability between buckle and greenstick fractures. Acta Orthop 2009; 80:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/14\">",
"      Chess DG, Hyndman JC, Leahey JL, et al. Short arm plaster cast for distal pediatric forearm fractures. J Pediatr Orthop 1994; 14:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/15\">",
"      Farbman KS, Vinci RJ, Cranley WR, et al. The role of serial radiographs in the management of pediatric torus fractures. Arch Pediatr Adolesc Med 1999; 153:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/16\">",
"      Bohm ER, Bubbar V, Yong Hing K, Dzus A. Above and below-the-elbow plaster casts for distal forearm fractures in children. A randomized controlled trial. J Bone Joint Surg Am 2006; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/17\">",
"      Symons S, Rowsell M, Bhowal B, Dias JJ. Hospital versus home management of children with buckle fractures of the distal radius. A prospective, randomised trial. J Bone Joint Surg Br 2001; 83:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/18\">",
"      West S, Andrews J, Bebbington A, et al. Buckle fractures of the distal radius are safely treated in a soft bandage: a randomized prospective trial of bandage versus plaster cast. J Pediatr Orthop 2005; 25:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/19\">",
"      Gaskin JS, Pimple MK, Wharton R, et al. How accurate and reliable are doctors in estimating fracture angulation? Injury 2007; 38:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/20\">",
"      Noonan KJ, Price CT. Forearm and distal radius fractures in children. J Am Acad Orthop Surg 1998; 6:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/21\">",
"      Do TT, Strub WM, Foad SL, et al. Reduction versus remodeling in pediatric distal forearm fractures: a preliminary cost analysis. J Pediatr Orthop B 2003; 12:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/22\">",
"      Boutis K, Willan A, Babyn P, et al. Cast versus splint in children with minimally angulated fractures of the distal radius: a randomized controlled trial. CMAJ 2010; 182:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/23\">",
"      Zimmermann R, Gschwentner M, Pechlaner S, Gabl M. Remodeling capacity and functional outcome of palmarly versus dorsally displaced pediatric radius fractures in the distal one-third. Arch Orthop Trauma Surg 2004; 124:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/24\">",
"      Stoffelen D, Broos P. Minimally displaced distal radius fractures: do they need plaster treatment? J Trauma 1998; 44:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/25\">",
"      Abid A, Accadbled F, Kany J, et al. Ulnar styloid fracture in children: a retrospective study of 46 cases. J Pediatr Orthop B 2008; 17:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/26\">",
"      Kim JK, Koh YD, Do NH. Should an ulnar styloid fracture be fixed following volar plate fixation of a distal radial fracture? J Bone Joint Surg Am 2010; 92:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/27\">",
"      Drendel AL, Gorelick MH, Weisman SJ, et al. A randomized clinical trial of ibuprofen versus acetaminophen with codeine for acute pediatric arm fracture pain. Ann Emerg Med 2009; 54:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/28\">",
"      Baitner AC, Perry A, Lalonde FD, et al. The healing forearm fracture: a matched comparison of forearm refractures. J Pediatr Orthop 2007; 27:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/29\">",
"      Golz RJ, Grogan DP, Greene TL, et al. Distal ulnar physeal injury. J Pediatr Orthop 1991; 11:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/30\">",
"      Berg EE. Pediatric distal double bone forearm fracture remodeling. Orthop Nurs 2005; 24:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14569/abstract/31\">",
"      Davis DR, Green DP. Forearm fractures in children: pitfalls and complications. Clin Orthop Relat Res 1976; :172.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6543 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14569=[""].join("\n");
var outline_f14_14_14569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2137856\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Absent pulse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2139229\">",
"      Open fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Analgesia and immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DEFINITIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Physeal fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Nondisplaced Salter I or II fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Displaced Salter I or II fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Salter III, IV, and V fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Torus (buckle) fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Greenstick fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Nondisplaced",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Mild displacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Moderate to severe displacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Complete fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2140102\">",
"      Ulnar styloid fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21531142\">",
"      Galeazzi fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      FRACTURE REDUCTION AND CASTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      DISCHARGE AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Home pain management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21531065\">",
"      Immobilization and return to activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6543|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/58/32672\" title=\"diagnostic image 1\">",
"      Salter III radius fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/18/32035\" title=\"diagnostic image 2\">",
"      Salter IV radius fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/48/14080\" title=\"diagnostic image 3\">",
"      Displaced Salter II fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/59/27583\" title=\"diagnostic image 4\">",
"      Colles fracture child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/52/20290\" title=\"diagnostic image 5\">",
"      Reduced Salter II fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/52/39744\" title=\"diagnostic image 6\">",
"      Buckle fracture radius",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/56/27520\" title=\"diagnostic image 7\">",
"      Buckle fracture radius ulna",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/44/30400\" title=\"diagnostic image 8\">",
"      Greenstick fracture radius",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/45/32478\" title=\"diagnostic image 9\">",
"      Greenstick fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/39/5745\" title=\"diagnostic image 10\">",
"      Midshaft fracture 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/33/19984\" title=\"diagnostic image 11\">",
"      Complete fracture radius",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/15/240\" title=\"diagnostic image 12\">",
"      Overlapping fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/3/11315\" title=\"diagnostic image 13\">",
"      Reduced overlapping fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/11/37055\" title=\"diagnostic image 14\">",
"      Unstable forearm fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/0/8194\" title=\"diagnostic image 15\">",
"      Ulnar styloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/49/36627\" title=\"diagnostic image 16\">",
"      Pediatric Galeazzi fracture and dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6543|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/26/37281\" title=\"figure 1\">",
"      Distal sugar tong splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21361\" title=\"figure 2\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/46/16096\" title=\"figure 3\">",
"      Three point cast molding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6543|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/19/4401\" title=\"picture 1\">",
"      Radial growth arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31368?source=related_link\">",
"      Closed reduction and casting of distal forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=related_link\">",
"      Diagnosis and assessment of distal forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11609?source=related_link\">",
"      Midshaft forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3546?source=related_link\">",
"      Proximal fractures of the forearm in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=related_link\">",
"      Treatment and prevention of osteomyelitis following trauma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_14_14570="Polyradiculopathy: spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes";
var content_f14_14_14570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Polyradiculopathy: spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14570/contributors\">",
"     Seward B Rutkove, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14570/contributors\">",
"     Andrew Tarulli, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14570/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/14/14570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/14/14570/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/14/14570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H179604\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyradiculopathy refers to damage to multiple nerve roots sufficient to produce neurologic symptoms and signs such as pain, weakness, and sensory loss. This topic will review the signs and symptoms of polyradiculopathy by spinal region, and provide an overview of the most common etiologies. Diagnostic testing and the differential diagnosis are also discussed.",
"   </p>",
"   <p>",
"    Cervical and lumbosacral radiculopathy are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179611\">",
"    <span class=\"h1\">",
"     PRESENTATION BY SPINAL LEVEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main feature that distinguishes radiculopathy from other neurologic disorders is that the symptoms and signs of radiculopathy follow sensory and motor nerve root distributions (",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53938 \" href=\"UTD.htm?22/19/22836\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50419 \" href=\"UTD.htm?10/36/10822\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68394 \" href=\"UTD.htm?24/52/25420\">",
"     table 1",
"    </a>",
"    ). However, since polyradiculopathy by definition affects multiple nerve roots, it can mimic conditions such as polyneuropathy, plexopathy, and mononeuropathy multiplex, making the diagnosis quite challenging. Often, objective signs such as weakness, sensory loss, and reflex change are mild in comparison to complaints of pain and paresthesia. Although there are certainly exceptions to this rule, the subtlety of physical examination findings in polyradiculopathy is a consequence of collateral motor and sensory innervation and incomplete nerve root damage.",
"   </p>",
"   <p>",
"    Although precise details as to the prevalence of polyradiculopathy by spinal region are not readily available, 60 to 90 percent of single-level radiculopathies occur in the lumbosacral levels. Cervical radiculopathy accounts for most of the balance, with thoracic radiculopathy representing only a small minority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/1\">",
"     1",
"    </a>",
"    ]. It is likely that polyradiculopathy also follows a similar prevalence by region.",
"   </p>",
"   <p>",
"    Cervical polyradiculopathy presents with neck pain radiating unilaterally or bilaterally into the arms with associated paresthesia, weakness, and sensory loss. The most common cause of cervical polyradiculopathy is degenerative cervical spondylosis, which can be accompanied by signs of cervical myelopathy such as spasticity and weakness in the lower extremities and bladder incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link\">",
"     \"Cervical spondylotic myelopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thoracic polyradiculopathy is the least common of the polyradiculopathies, mainly because spinal stenosis and associated foraminal narrowing in this region is generally modest, even in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Symptoms include pain and paresthesia in the chest and abdomen and, occasionally, abdominal wall weakness with herniation of abdominal contents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lumbosacral polyradiculopathy accounts for the majority of polyradiculopathy cases. Central canal spinal stenosis in this region classically presents as neurogenic claudication, characterized by an aching that begins in the buttocks and descends into the knees, is brought on by walking or exercise, and is relieved by forward flexion (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link&amp;anchor=H6#H6\">",
"     \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\", section on 'Symptoms'",
"    </a>",
"    ). Spinal stenosis may also affect the lateral recesses, producing compression of multiple nerve roots without claudication symptoms. Diabetic amyotrophy is another well-known, but less common cause of lumbosacral polyradiculopathy-like symptoms, although the exact localization of this disorder remains unresolved (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A variant of lumbosacral polyradiculopathy is the cauda equina syndrome, in which the cauda equina itself is compressed within the spinal canal. The most common cause for this is a large, central disc herniation or central spinal canal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/6\">",
"     6",
"    </a>",
"    ]. Cauda equina syndrome is generally considered a neurologic emergency characterized by progressive lower extremity weakness, sphincter dysfunction, and saddle anesthesia. Other causes of cauda equina syndrome include epidural abscess, epidural tumor, intradural extramedullary tumor, the tethered cord syndrome, inflammatory conditions including spinal arachnoiditis, chronic inflammatory demyelinating polyneuropathy, and sarcoidosis. The cauda equina syndrome can also be caused by infection with cytomegalovirus, herpes simplex virus, herpes zoster virus, Epstein-Barr virus, Lyme disease, mycoplasma and tuberculosis. In the case of acute disk herniation, cauda equina syndrome may require urgent surgical evaluation and treatment to preserve neurologic function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H22#H22\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Cauda equina syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179618\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologies of polyradiculopathy can generally be divided into structural (or surgical) and nonstructural (or medical) categories (",
"    <a class=\"graphic graphic_table graphicRef81525 \" href=\"UTD.htm?21/51/22333\">",
"     table 2",
"    </a>",
"    ). The most common etiologies, along with their evaluation and treatment, will be discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179625\">",
"    <span class=\"h2\">",
"     Spinal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal stenosis refers to the narrowing of the spinal canal or intervertebral foramina. The majority of cases of spinal stenosis are caused by degenerative change (spondylosis), which is reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link&amp;anchor=H8#H8\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\", section on 'Degenerative changes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link&amp;anchor=H4#H4\">",
"     \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\", section on 'Pathophysiology'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Presenting with increasing frequency in the sixth and seventh decades, the initiating change in degenerative spinal stenosis is desiccation of the intervertebral discs. As a result of disc desiccation and loss of disc height, the posterior elements of the spine, including the facet joints and ligamentum flavum, become increasingly involved in axial load bearing. The stress placed on these structures results in compensatory bony and ligamentous hypertrophy and osteophyte formation, which narrows both the diameter of the central spinal canal and the neural foramina. Because the degenerative process occurs at multiple levels, polyradiculopathy often results.",
"   </p>",
"   <p>",
"    Additional causes of spinal stenosis (",
"    <a class=\"graphic graphic_table graphicRef81525 \" href=\"UTD.htm?21/51/22333\">",
"     table 2",
"    </a>",
"    ) include congenital conditions, such as hereditary spinal stenosis or achondroplasia, and systemic conditions such as ankylosing spondylitis or Paget disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms and signs of polyradiculopathy due to spinal stenosis vary according to spinal level:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the cervical level, symptoms of polyradiculopathy in isolation include arm pain, paresthesias, weakness, and sensory loss (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"       \"Clinical features and diagnosis of cervical radiculopathy\"",
"      </a>",
"      ). More worrisome symptoms include simultaneous evidence of actual spinal cord dysfunction (ie, cervical myelopathy), characterized by leg weakness, gait difficulty, and incontinence of bowel or bladder. This condition is a potential neurologic emergency and may require urgent decompressive surgery (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link\">",
"       \"Cervical spondylotic myelopathy\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Lumbar spinal stenosis may produce lower back pain radiating into the leg, as occurs in herniated nucleus pulposus, or the clinical syndrome of neurogenic claudication [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients with neurogenic claudication characteristically experience aching that begins in the buttocks and descends to the knees, is brought on by walking or exercise, and is relieved by forward flexion. This can be distinguished from the symptoms of vascular claudication of the lower extremities, which is also characterized by pain with exercise. True vascular claudication is relieved by shorter rest periods, is not aggravated by lumbar extension, is accompanied by diminished or absent lower extremity pulses, and is often quite asymmetric. Central canal stenosis of the lumbar spine may also produce the cauda equina syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link&amp;anchor=H5#H5\">",
"       \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\", section on 'Clinical presentation'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Magnetic resonance imaging has become the test of choice in the evaluation of spinal stenosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59200 \" href=\"UTD.htm?43/19/44339\">",
"     image 1",
"    </a>",
"    ), although bony changes such as osteophyte formation are better demonstrated by CT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link&amp;anchor=H10#H10\">",
"     \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the radiographic changes of spinal stenosis are so common in older patients, however, the history and physical examination remain critical in establishing the relevance of neuroimaging findings and determining appropriate therapy. Electrodiagnostic studies are often required to confirm the diagnosis when the clinical presentation is ambiguous (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Electrodiagnostic studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link&amp;anchor=H26#H26\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\", section on 'Electrodiagnosis'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The management of spinal stenosis and its associated manifestations is discussed separately in appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17144?source=see_link\">",
"     \"Treatment of cervical radiculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link&amp;anchor=H12#H12\">",
"     \"Cervical spondylotic myelopathy\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=see_link\">",
"     \"Acute lumbosacral radiculopathy: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22776?source=see_link\">",
"     \"Lumbar spinal stenosis: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179639\">",
"    <span class=\"h2\">",
"     Tethered cord syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tethered cord syndrome is a developmental anomaly usually seen in children (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=see_link&amp;anchor=H19221535#H19221535\">",
"     \"Pathogenesis and types of occult spinal dysraphism\", section on 'Tethered cord syndrome'",
"    </a>",
"    ). It can also produce polyradiculopathy in adults. During early development, a defect in the dura mater allows communication of the spinal cord with subcutaneous tissues, anchoring the conus medullaris and preventing the normal upward migration of the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tethered cord syndrome presents in childhood or in adulthood as pain in the lower extremities and perianal region, progressive weakness, sensory disturbances, and sphincter dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Because the cauda equina and conus medullaris are affected, both spastic and flaccid bowel and bladder dysfunction may be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/14\">",
"     14",
"    </a>",
"    ]. In most adult cases, motor weakness does not follow a strict myotomal pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adult-onset tethered cord syndrome, cutaneous signs of spinal dysraphism, such as sacral dimples or tufts of hair over the lumbosacral spine, are present in approximately 35 percent of cases, whereas such findings are typical in pediatric-onset cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI usually demonstrates a low lying termination of the conus medullaris below the inferior aspect of the L2 vertebral body (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75372 \" href=\"UTD.htm?20/32/20995\">",
"     image 2",
"    </a>",
"    ), but occasionally the conus level is at or above",
"    <span class=\"nowrap\">",
"     L2/L3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/15\">",
"     15",
"    </a>",
"    ]. Associated structural abnormalities on MRI may include a thickened filum terminale, an intradural or extradural lipoma, a myelomeningocele, fibrous adhesions around the conus or the filum, a split cord malformation, and various types of cyst (eg, arachnoid, dermoid, enteric).",
"   </p>",
"   <p>",
"    Surgical treatment of tethered cord syndrome involves lumbar or sacral laminectomy with sectioning of the thickened filum terminale [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/14\">",
"     14",
"    </a>",
"    ]. A systematic review of over 451 adult cases of tethered cord syndrome published in 2008 reported that surgery was associated with improvement in pain and motor deficits in 83 and 59 percent of patients respectively, while sphincter and sensory deficits improved in 46 and 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/15\">",
"     15",
"    </a>",
"    ]. Most of the included studies were uncontrolled series or case reports, and few patients were followed beyond two years after surgery. Thus, the benefit of surgery for tethered cord syndrome is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179653\">",
"    <span class=\"h2\">",
"     Primary tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of primary tumors may cause polyradiculopathy (",
"    <a class=\"graphic graphic_table graphicRef81525 \" href=\"UTD.htm?21/51/22333\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The one that most characteristically does so is ependymoma, classically presenting as a cauda equina syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/19\">",
"     19",
"    </a>",
"    ]. Surgery is the preferred treatment for most primary tumors that produce polyradiculopathy, with the need for postoperative radiotherapy and chemotherapy dictated by tumor histology and the completeness of the surgical resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15161?source=see_link\">",
"     \"Ependymoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link\">",
"     \"Spinal cord tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179667\">",
"    <span class=\"h2\">",
"     Leptomeningeal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer arising outside the central nervous system can metastasize to any structure of the central nervous system, including the membranes covering the brain and spinal cord. These membranes consist of the dura mater, the arachnoid, and the pia mater. The latter two are together called the leptomeninges. Tumor involvement of the leptomeninges is a condition termed leptomeningeal metastases. It is also known by a variety of synonyms, including meningeal carcinomatosis, carcinomatous meningitis, and neoplastic meningitis. This disorder is reviewed here briefly and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cluster of symptoms related to leptomeningeal metastases is widespread (",
"    <a class=\"graphic graphic_table graphicRef74299 \" href=\"UTD.htm?33/4/33868\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/20\">",
"     20",
"    </a>",
"    ]. Leptomeningeal metastases can cause polyradiculopathy by direct involvement of the spinal nerve roots, and radicular pain is the most common presenting symptom. In addition, infiltration of the leptomeninges and subarachnoid space can produce headache, memory loss, seizures, cranial polyneuropathy, and gait disturbances. The primary malignancies that most frequently produce this syndrome are leukemia, lymphoma, breast cancer, lung cancer, melanoma, and gastrointestinal cancers.",
"   </p>",
"   <p>",
"    The classic cerebrospinal fluid (CSF) findings of leptomeningeal metastases include a high opening pressure, low glucose concentration, high protein concentration, lymphocytic pleocytosis, and positive cytology for malignant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Although most patients do not have all of these features, an entirely normal CSF examination is uncommon. Initial CSF examination reveals a mildly increased cell count in 50 to 60 percent of patients, elevated protein in a large majority, and low glucose in about 30 percent. In most cases, a positive cytology can be obtained with two separate samplings. However, CSF cytology is persistently negative in as many as 20 percent of patients with clinically or radiographically unequivocal leptomeningeal metastases. MRI may reveal contrast enhancement of the meninges and nerve roots in a diffuse or nodular pattern (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60153 \" href=\"UTD.htm?20/53/21329\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis of leptomeningeal metastases is straightforward in the patient with advanced cancer, multifocal signs and symptoms, typical imaging findings by MRI, and positive CSF cytology. An enhanced MRI of the symptomatic region of brain or spine should be obtained prior to obtaining CSF by lumbar puncture or ventricular tap, because the latter procedures can cause iatrogenic meningeal enhancement. A positive CSF cytology establishes the diagnosis of leptomeningeal metastases. At least two CSF samples, with a combined total of 30 mL, should be evaluated. However, obtaining CSF for cytology may be unnecessary in patients with typical signs and symptoms, characteristic MRI findings, and known widespread malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of leptomeningeal metastases arising from solid tumors is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of leptomeningeal metastases in hematologic malignancies, especially large cell lymphomas and acute leukemias, is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Leptomeningeal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179681\">",
"    <span class=\"h2\">",
"     Diabetic thoracic radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic thoracic radiculopathy is an uncommon syndrome that tends to affect patients with poorly-controlled diabetes of long duration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinical features are severe, sharp or burning pain and paresthesias in the abdominal or chest well [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Some patients may have associated abdominal muscle weakness with abdominal wall herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Polyradiculopathy occurs in approximately 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnostic electromyographic findings are fibrillation potentials in the abdominal oblique muscles, rectus abdominus, intercostal muscles, and thoracic paraspinal muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In general, the prognosis for patients with diabetic thoracic polyradiculopathy is good, with 11 of 12 patients in one series achieving remission within two years, the majority of these within the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/2\">",
"     2",
"    </a>",
"    ]. Spontaneous resolution is also noted in patients with abdominal wall bulging [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/4\">",
"     4",
"    </a>",
"    ]. During the acute phase of illness, however, pain control may be challenging.",
"   </p>",
"   <p>",
"    Patients with suspected thoracic radiculopathy should undergo electromyography and nerve conduction studies to confirm the localization. Although disc herniations and spinal stenosis are uncommon at thoracic levels, MRI of the thoracic spine should be performed to exclude structural causes of radiculopathy. We suggest treatment with agents for neuropathic pain administered in the acute phase, such as tricyclic agents, dual reuptake inhibitors of serotonin and norepinephrine or calcium channel alpha 2-delta ligands (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link&amp;anchor=H185828303#H185828303\">",
"     \"Overview of the treatment of chronic pain\", section on 'Neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our preferred agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    titrated to 1200 mg three times daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    titrated to 100 mg daily at bedtime. In our clinical experience, patients often have a prompt and dramatic reduction in pain with this approach. For patients who do not improve with these agents, we also consider a short course of oral glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 60 mg daily for one to two weeks, followed by a taper) with careful glycemic control being maintained throughout the treatment period. However, there is no study clearly supporting the use of oral glucocorticoids for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179695\">",
"    <span class=\"h2\">",
"     Diabetic amyotrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic amyotrophy is reviewed here briefly and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic amyotrophy is a condition referred to by many names, including diabetic lumbosacral polyradiculoneuropathy, proximal diabetic neuropathy, diabetic lumbosacral plexopathy, and Bruns-Garland syndrome. It is not a pure lumbosacral plexopathy because it also affects the lumbosacral nerve roots and peripheral nerves. The most likely cause of diabetic amyotrophy and the clinically similar condition of idiopathic lumbosacral radiculoplexus neuropathy is ischemic injury from a nonsystemic microvasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H2#H2\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Background'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic amyotrophy usually affects patients with type 2 diabetes of middle or older age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Diabetic amyotrophy may be the first symptom of diabetes, and most patients who develop the condition do not have poorly-controlled diabetes. The traditional features include the acute, asymmetric, focal onset of pain followed by weakness involving the proximal leg, with associated autonomic failure and weight loss. Progression occurs over months and is followed by partial recovery in most patients. However, onset in the distal leg is not uncommon. Furthermore, the condition becomes more widespread and symmetric with time. In nearly all cases, the symptoms and signs progress to affect the contralateral limb and the distal legs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H3#H3\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of diabetic amyotrophy is based upon the presence of suggestive clinical features in a patient with known or newly diagnosed diabetes mellitus. Appropriate laboratory investigations, particularly electrodiagnostic studies, and neuroimaging in select patients, are useful to exclude other peripheral and central nervous system etiologies as a cause of the neurologic symptoms and signs. Abnormalities on electrodiagnostic studies typically involve the lumbar and sacral roots, the lumbosacral plexus, and the peripheral nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/25\">",
"     25",
"    </a>",
"    ]. Nerve conduction studies show markedly reduced amplitudes of the compound muscle action potentials and sensory nerve action potentials, while conduction velocities show only mild slowing. Needle electromyography shows fibrillation potentials, decreased motor unit recruitment, and long-duration, high amplitude motor unit action potentials. Paraspinal muscles are typically involved; this finding demonstrates that pathology must exist outside of the lumbosacral plexus. In patients who do not have diabetes, idiopathic lumbosacral radiculoplexus neuropathy is the primary consideration in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H6#H6\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While clinical improvement is the rule with diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy, most patients do not recover completely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H10#H10\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No treatments are proven to be effective for diabetic amyotrophy or for idiopathic lumbosacral radiculoplexus neuropathy. Symptomatic management is the mainstay of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link&amp;anchor=H11#H11\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179709\">",
"    <span class=\"h2\">",
"     Lyme disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is a tick-borne illness caused by three pathogenic species of the spirochete Borrelia (B. burgdorferi, B. afzelii and B. garinii). The neurologic manifestations of Lyme disease are reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14681?source=see_link\">",
"     \"Nervous system Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphocytic meningitis, cranial neuropathy (particularly facial palsy) and radiculoneuritis (motor or sensory or both) are the three most common presentations of acute, early neurologic Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. These manifestations may occur alone or in combination, but radiculoneuritis is less common than meningitis or facial palsy in the United States. Peripheral nerve involvement in Lyme disease primarily consists of a multifocal axonal process (",
"    <a class=\"graphic graphic_table graphicRef77485 \" href=\"UTD.htm?2/58/2987\">",
"     table 4",
"    </a>",
"    ). Lyme radiculoneuritis is reported in approximately 3 percent of Lyme disease cases in the United States. Lyme radiculoneuritis can mimic a mechanical radiculopathy (eg, sciatica) with radicular pain in one or several dermatomes, accompanied by corresponding sensory, motor and reflex changes. This disorder should be considered in patients in endemic areas presenting in spring through autumn with severe limb or truncal radicular pain without an apparent mechanical precipitant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14681?source=see_link&amp;anchor=H10939468#H10939468\">",
"     \"Nervous system Lyme disease\", section on 'Radiculoneuritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In European neuroborreliosis, the term Garin-Bujadoux-Bannwarth syndrome (or Bannwarth syndrome) has been applied to the constellation of painful radiculoneuritis, often accompanied by meningitis with minimal headache and sometimes with cranial neuropathy. Thus, painful radiculoneuritis is usually the hallmark of the syndrome. In the United States, radiculoneuritis is a less prominent part of the picture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14681?source=see_link&amp;anchor=H30180706#H30180706\">",
"     \"Nervous system Lyme disease\", section on 'Bannwarth syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of nervous system Lyme disease rests on three elements (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14681?source=see_link&amp;anchor=H10939504#H10939504\">",
"     \"Nervous system Lyme disease\", section on 'Diagnosis'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Since the disease is transmitted exclusively by bites of Ixodes ticks, there must be the possibility of exposure",
"     </li>",
"     <li>",
"      The clinical disorder should include features that have been associated with nervous system Lyme disease",
"     </li>",
"     <li>",
"      Laboratory testing (positive Lyme serologies with or without positive Lyme antibodies in the cerebrospinal fluid) should support the diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the exception of the first four to six weeks of infection, serologic testing is highly sensitive and specific for the diagnosis of Lyme disease, particularly when employing the two-tier strategy, which uses a sensitive enzyme-linked immunosorbent assay followed by a Western blot. Except in those uncommon instances when cranial neuropathies or radiculopathies occur in this very early time window, the diagnosis of nervous system Lyme disease should be made only with extreme caution in patients who are seronegative. The absence of detectable antibodies in the serum is usually strong evidence against the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14681?source=see_link&amp;anchor=H4821958#H4821958\">",
"     \"Nervous system Lyme disease\", section on 'Serologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A cerebrospinal fluid (CSF) pleocytosis (typically lymphocytic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    monocytic), a moderately elevated protein concentration, and a relatively normal glucose concentration are often seen in patients presenting with Lyme meningitis several weeks into the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14681?source=see_link&amp;anchor=H4821965#H4821965\">",
"     \"Nervous system Lyme disease\", section on 'CSF analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory testing must be tailored to the individual circumstances. When considering meningitis, the CSF should be examined, primarily to exclude other diagnoses. CSF and serum assessment for anti-B. burgdorferi antibodies can be informative if an inflammatory central nervous system process is apparent. CSF analysis is of limited utility if disease is limited to the peripheral nervous system. MRI of the neuraxis is helpful when symptoms or clinical findings point to a focal process, primarily to exclude other diagnoses. Polymerase chain reaction for B. burgdorferi is of extremely limited utility and is not recommended for routine testing of CSF in Lyme disease. Electromyography and nerve conduction studies can be helpful in addressing the differential diagnosis, particularly if peripheral nerve involvement is disseminated. Most patients with typical painful Lyme radiculoneuritis have widespread abnormalities on nerve conduction studies, including abnormal sensory nerve action potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14681?source=see_link&amp;anchor=H24976859#H24976859\">",
"     \"Nervous system Lyme disease\", section on 'Approach to diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of nervous system Lyme disease is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of Lyme disease\", section on 'Acute neurologic manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of Lyme disease\", section on 'Late neurologic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179723\">",
"    <span class=\"h2\">",
"     Polyradiculopathy in HIV and AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapidly progressing lumbosacral polyradiculopathy (cauda equina syndrome) occurs mainly in HIV-infected patients with severe immunosuppression. The most common cause is cytomegalovirus infection, followed by neurosyphilis and lymphomatous meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Since the advent of highly active antiretroviral therapy, this clinical entity is uncommonly seen, except in the untreated patient with advanced AIDS.",
"   </p>",
"   <p>",
"    The clinical picture is dominated by the subacute onset of lower extremity weakness and numbness in a patient with advanced HIV-related immunosuppression and often a prior diagnosis of cytomegalovirus disease in other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/34\">",
"     34",
"    </a>",
"    ]. Sensory dysesthesias can begin in the feet or in the saddle region from involvement of sacral roots. Symptoms can be asymmetric, especially early in the course of the disease. Clinical progression occurs rapidly over days to flaccid paraparesis or paraplegia with urinary retention and sphincter dysfunction. A less fulminant, more slowly progressing variant has also been described. On examination, a lumbar sensory level and lower extremity areflexia with saddle anesthesia can be demonstrated. Sacral radiculomyelitis can also be seen secondary to genital herpes simplex virus infection; this syndrome can occur at any stage of HIV disease. Radiculomyelitis has also been reported rarely with syphilis and tuberculosis infection in HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\", section on 'Lumbosacral polyradiculopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lumbar puncture characteristically shows cerebrospinal fluid (CSF) pleocytosis, frequently predominated by polymorphonuclear cells, elevated protein and, in a minority of patients, decreased glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]; with lymphomatous meningitis, the CSF typically reveals a lymphocytic pleocytosis. Cytomegalovirus can be cultured from the CSF in some cases. Viral culture cannot be used as the sole means of diagnosis because of false negative results and the fact that viral cultures may not turn positive for up to a week [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/33,37\">",
"     33,37",
"    </a>",
"    ]. Polymerase chain reaction testing for cytomegalovirus DNA in the CSF can provide a more rapid diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/38\">",
"     38",
"    </a>",
"    ]. Testing for syphilitic polyradiculopathy in these cases is also recommended; a negative treponemal serologic test in the serum or CSF renders this diagnosis unlikely. Electrophysiologic studies can help confirm the presence of polyradiculopathy and exclude a polyradiculoneuropathy; sensory action potentials are present in patients with a polyradiculopathy but are abnormal in patients with a polyradiculoneuropathy. MRI of the spine should be performed mainly to exclude structural lesions and cauda equina compression. Cauda equina root enhancement with contrast-enhanced MRI is seen in many, but not all, patients with cytomegalovirus-related polyradiculopathy. However, this finding is not specific and is seen in other inflammatory and neoplastic conditions involving the cauda equina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis, treatment and prognosis of HIV-associated neuropathies\", section on 'Lumbosacral polyradiculopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of HIV-associated neuropathies is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis, treatment and prognosis of HIV-associated neuropathies\", section on 'Treatment and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179737\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of polyradiculopathy can be made on purely clinical grounds in most cases. However, localization of the problem to multiple nerve roots is often challenging, because lesions of the brachial or lumbosacral plexus, peripheral nerves, or central nervous system can present similarly. The tests that are most useful in establishing a diagnosis of polyradiculopathy are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Electromyography and nerve conduction studies",
"     </li>",
"     <li>",
"      Magnetic resonance imaging with and without contrast",
"     </li>",
"     <li>",
"      Lumbar puncture for cerebrospinal fluid analyses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179744\">",
"    <span class=\"h2\">",
"     Electrodiagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies allow the differentiation between radiculopathy and other neurologic conditions such as polyneuropathy, compression neuropathy, myopathy, plexopathy, and motor neuron disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most useful electrodiagnostic finding in patients with radiculopathy is an abnormal needle electromyography (EMG). Needle EMG can provide evidence for physiological abnormalities consistent with a radiculopathy, grade the extent and severity of injury, and determine its duration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/39\">",
"     39",
"    </a>",
"    ]. One major limitation to needle EMG is in patients with polyradiculopathy predominantly affecting the dorsal roots, in whom substantial pain may be present, but no abnormalities on needle EMG identified.",
"   </p>",
"   <p>",
"    Needle EMG findings follow the distribution of a nerve root and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute (less than one week): reduced recruitment",
"     </li>",
"     <li>",
"      Subacute (between one week and three months): reduced recruitment, fibrillation potentials, and positive sharp waves",
"     </li>",
"     <li>",
"      Chronic (greater than three months): increased motor unit potential amplitude, duration, and polyphasic motor unit potentials",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity of the needle EMG in patients with cervical radiculopathy varies from 50 to 72 percent, while in patients with suspected lumbosacral radiculopathy, needle EMG has a sensitivity of 36 to 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Several limitations of the technique explain these modest sensitivities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients with radiculopathy have pain and paresthesias alone and lack the motor involvement required to produce needle electromyographic abnormalities",
"     </li>",
"     <li>",
"      Abnormal spontaneous activity requires seven days before it appears in paraspinal muscles and several weeks to appear in limb muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fibrillation potentials and positive sharp waves will disappear with time as reinnervation leads to recovery or chronic injury leads to loss of some muscle reactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nerve conduction studies are routinely performed in conjunction with EMG. They are most effective in eliminating polyneuropathy, plexopathy, and compression neuropathy as diagnostic considerations. However, nerve conduction studies have several limitations in establishing the diagnosis of polyradiculopathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional nerve conduction studies assess a small number of spinal levels, predominantly C8-T1 in the upper extremities and L5-S1 in the lower extremities.",
"     </li>",
"     <li>",
"      Compound motor action potential (CMAP) amplitude abnormalities are relatively uncommon in radiculopathy: for patients with",
"      <span class=\"nowrap\">",
"       L5/S1",
"      </span>",
"      radiculopathies, CMAPs were absent from the extensor digitorum brevis or flexor digitorum brevis muscles in only 6 percent, and amplitudes were decreased in just 24.1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/44\">",
"       44",
"      </a>",
"      ]. The likelihood of finding CMAP abnormalities in patients with radiculopathy is reduced by overlapping nerve root innervation and the usually incomplete nature of root injury. For similar reasons, slowing of motor conduction velocities between proximal and distal stimulation sites is uncommon and, if present, limited in degree [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normal sensory nerve action potential (SNAP) amplitudes favor a diagnosis of radiculopathy rather than plexopathy or polyneuropathy because nerve root injury in radiculopathy is most often proximal to the dorsal root ganglion [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/39\">",
"       39",
"      </a>",
"      ]. Nerve fiber degeneration therefore occurs in the axon that projects centrally from the dorsal root ganglion rather than from the one that projects peripherally. However, in inflammatory and neoplastic lesions, damage may occur distal to the dorsal root ganglion and consequently produce abnormal SNAPs. In addition, the SNAP amplitude may be reduced in a subset of patients with L5 nerve root involvement due to the dorsal root ganglia being located within the spinal canal itself [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The late responses known as the H reflex and F wave may be useful in the evaluation of polyradiculopathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The H reflex is similar to a deep tendon reflex (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=see_link&amp;anchor=H4#H4\">",
"       \"Nerve conduction studies: Late responses\", section on 'H reflex'",
"      </a>",
"      ). The main limitation of the H reflex test is that it is commonly obtainable only from the soleus and occasionally from the flexor carpi radialis, which restricts the number of spinal levels that it can assess. It is also somewhat nonspecific, being affected in disorders that injure the neurons anywhere along their path. However, one study that evaluated normal controls and those with an L5 or S1 radiculopathy found that the H reflex for S1 radiculopathy had a sensitivity and specificity of 50 and 91 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/46\">",
"       46",
"      </a>",
"      ]. In a broader patient population referred for polyradiculopathy, in whom polyneuropathy, cervical monoradiculopathy, and plexopathy are the main considerations in the differential diagnosis, the sensitivity of the H reflex would likely increase while the specificity would likely decrease.",
"     </li>",
"     <li>",
"      F waves are produced by antidromic activation of motor neurons (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=see_link&amp;anchor=H2#H2\">",
"       \"Nerve conduction studies: Late responses\", section on 'F waves'",
"      </a>",
"      ). F response latency was abnormal in 69 percent of 39 tibial and peroneal nerves in one study of patients with spinal stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/47\">",
"       47",
"      </a>",
"      ]. Other studies reported that the sensitivity of prolonged F response latency was 70 to 80 percent in patients with L5-S1 monoradiculopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/39\">",
"       39",
"      </a>",
"      ]. Although the sensitivity of F response abnormalities for radiculopathy is relatively high, the specificity is limited, as any injury along the entirety of the nerve that is being stimulated may produce prolonged F responses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179751\">",
"    <span class=\"h2\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is the single best test for demonstrating structural pathology responsible for polyradiculopathy. Although spinal stenosis is readily identifiable on MRI, because degenerative changes of the spine are so common with age, the clinical history and examination are often the crucial factors in making a diagnosis of polyradiculopathy. Polyradiculopathy of infectious, inflammatory or neoplastic origin may be accompanied by abnormal contrast enhancement of the nerve roots or may be entirely normal, but when these conditions are suspected, a contrast-enhanced MRI is essential to exclude more common structural causes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/14/14570/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179758\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;When no clear structural source for polyradiculopathy is identified on MRI, lumbar puncture is often the next step in evaluation. Although lumbar puncture may not establish a specific diagnosis, cerebrospinal fluid (CSF) abnormalities may guide further testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In leptomeningeal metastases, the CSF white blood cell count is increased in &gt;50 percent, the CSF protein is increased in approximately 80 percent, the CSF glucose is &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in 25 to 30 percent, and CSF cytology is positive for malignant cells in 80 to 90 percent with sufficient CSF sampling. (See",
"      <a class=\"local\" href=\"#H179667\">",
"       'Leptomeningeal metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In Lyme meningitis, with or without radiculoneuritis, the CSF white count is elevated, predominated by lymphocytes or monocytes, the CSF protein is usually elevated, the CSF glucose concentration is usually normal. However, CSF analysis is of limited utility if disease is limited to the peripheral nervous system. (See",
"      <a class=\"local\" href=\"#H179709\">",
"       'Lyme disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In lumbosacral polyradiculopathy associated with",
"      <span class=\"nowrap\">",
"       HIV/AIDS,",
"      </span>",
"      the CSF white blood cell count is increased, frequently predominated by polymorphonuclear cells, the CSF protein is increased, and the CSF glucose is normal or decreased, and CSF cultures are positive for cytomegalovirus in approximately 50 percent of cases. (See",
"      <a class=\"local\" href=\"#H179723\">",
"       'Polyradiculopathy in HIV and AIDS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179765\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the multiple nerve roots that are affected in polyradiculopathy may lead to widespread complaints that can be confused with a variety of neurologic, musculoskeletal, and vascular disorders.",
"   </p>",
"   <p>",
"    Although most polyradiculopathies produce pain and paresthesias, pure motor presentations can mimic central nervous system conditions including cerebrovascular infarction or hemorrhage, demyelinating disease, and brain neoplasms. These conditions can be differentiated from polyradiculopathy by increased tone, hyperactive reflexes, and abnormal neuroimaging findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=see_link&amp;anchor=H11#H11\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\", section on 'Distinguishing peripheral from central nervous system disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Motor neuron disease is a neurodegenerative disorder of upper and lower motor neurons that can be difficult to distinguish from polyradiculopathy. Careful physical examination and electromyography to detect abnormalities of bulbar muscles and mid-thoracic paraspinal muscles help to establish this diagnosis. The absence of any sensory complaints and pain is also suggestive of motor neuron disease over polyradiculopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of peripheral nervous system disorders can imitate polyradiculopathy, and electrodiagnostic testing is often required to establish a clear diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plexopathy is most often characterized by weakness and pain affecting multiple myotomes and dermatomes, and may be the single condition that most closely resembles polyradiculopathy on a clinical level. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link\">",
"       \"Brachial plexus syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link\">",
"       \"Lumbosacral plexus syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myopathy is usually symmetric, and rarely produces the same degree of pain, and never the same objective sensory findings that are seen in polyradiculopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link&amp;anchor=H12#H12\">",
"       \"Approach to the patient with muscle weakness\", section on 'Myopathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Polyneuropathy is typically distal and symmetric, but exceptions to these rules can produce a presentation similar to polyradiculopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"       \"Overview of polyneuropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Musculoskeletal conditions such as tendonitis, myofascial pain syndrome, fibromyalgia, and bursitis can occasionally be confused with polyradiculopathy. Although they are characterized by pain without sensory loss or weakness, the pain produced by these conditions can result in functional weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=see_link\">",
"     \"Overview of soft tissue rheumatic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, vascular disease of the lower extremities can produce claudication symptoms that can be differentiated from neurogenic claudication by improvement after shorter rest periods, prominent asymmetry, lack of aggravation by lumbar spine extension, and diminution or absence of peripheral pulses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thoracic polyradiculopathy is often not initially suspected until more common intrathoracic and abdominal processes such as cardiac ischemia or gastrointestinal disease are eliminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85616251\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main feature that distinguishes radiculopathy from other neurologic disorders is that the symptoms and signs of radiculopathy follow sensory and motor nerve root distributions (",
"      <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53938 \" href=\"UTD.htm?22/19/22836\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50419 \" href=\"UTD.htm?10/36/10822\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68394 \" href=\"UTD.htm?24/52/25420\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H179611\">",
"       'Presentation by spinal level'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cervical polyradiculopathy presents with neck pain radiating unilaterally or bilaterally into the arms with associated paresthesia, weakness, and sensory loss.",
"     </li>",
"     <li>",
"      Thoracic polyradiculopathy is the least common of the polyradiculopathies; symptoms include pain and paresthesia in the chest and abdomen and, occasionally, abdominal wall weakness with herniation of abdominal contents.",
"     </li>",
"     <li>",
"      Lumbosacral polyradiculopathy accounts for the majority of polyradiculopathy cases. Central canal spinal stenosis in this region classically presents as neurogenic claudication, characterized by an aching that begins in the buttocks and descends into the knees, is brought on by walking or exercise, and is relieved by forward flexion.",
"     </li>",
"     <li>",
"      The cauda equina syndrome, a variant of lumbosacral polyradiculopathy, is characterized by progressive lower extremity weakness, sphincter dysfunction, and saddle anesthesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiologies of polyradiculopathy can generally be divided into structural (or surgical) and nonstructural (or medical) categories (",
"      <a class=\"graphic graphic_table graphicRef81525 \" href=\"UTD.htm?21/51/22333\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Spinal stenosis refers to the narrowing of the spinal canal or intervertebral foramina. The majority of cases of spinal stenosis are caused by degenerative change (spondylosis). (See",
"      <a class=\"local\" href=\"#H179625\">",
"       'Spinal stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tethered cord syndrome is a developmental anomaly usually seen in children that can also produce polyradiculopathy in adults. (See",
"      <a class=\"local\" href=\"#H179639\">",
"       'Tethered cord syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of primary tumors may cause polyradiculopathy. (See",
"      <a class=\"local\" href=\"#H179653\">",
"       'Primary tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leptomeningeal metastases can cause polyradiculopathy by direct involvement of the spinal nerve roots; radicular pain is the most common presenting symptom. (See",
"      <a class=\"local\" href=\"#H179667\">",
"       'Leptomeningeal metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic thoracic radiculopathy is an uncommon syndrome that tends to affect patients with poorly-controlled diabetes of long duration. (See",
"      <a class=\"local\" href=\"#H179681\">",
"       'Diabetic thoracic radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic amyotrophy is a type of lumbosacral plexopathy that also affects the lumbosacral nerve roots and peripheral nerves. (See",
"      <a class=\"local\" href=\"#H179695\">",
"       'Diabetic amyotrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lyme disease may affect the nervous system; the classic manifestations are lymphocytic meningitis, cranial neuropathy and radiculoneuritis, alone or in combination. (See",
"      <a class=\"local\" href=\"#H179709\">",
"       'Lyme disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A rapidly progressing lumbosacral polyradiculopathy (cauda equina syndrome) occurs mainly in HIV-infected patients with severe immunosuppression. (See",
"      <a class=\"local\" href=\"#H179723\">",
"       'Polyradiculopathy in HIV and AIDS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A diagnosis of polyradiculopathy can be made on purely clinical grounds in most cases. However, localization of the problem to multiple nerve roots is often challenging because lesions of the brachial or lumbosacral plexus, peripheral nerves, or central nervous system can present similarly. The tests that are most useful for establishing a diagnosis of polyradiculopathy are electromyography and nerve conduction studies, MRI of the relevant spinal level with and without contrast, and lumbar puncture for cerebrospinal fluid analyses. (See",
"      <a class=\"local\" href=\"#H179737\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The multiple nerve roots that are affected in polyradiculopathy may lead to widespread complaints that can be confused with a variety of neurologic, musculoskeletal, and vascular disorders. (See",
"      <a class=\"local\" href=\"#H179765\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/1\">",
"      Wilbourn AJ, Aminoff MJ. AAEM minimonograph 32: the electrodiagnostic examination in patients with radiculopathies. American Association of Electrodiagnostic Medicine. Muscle Nerve 1998; 21:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/2\">",
"      Kikta DG, Breuer AC, Wilbourn AJ. Thoracic root pain in diabetes: the spectrum of clinical and electromyographic findings. Ann Neurol 1982; 11:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/3\">",
"      Sun SF, Streib EW. Diabetic thoracoabdominal neuropathy: clinical and electrodiagnostic features. Ann Neurol 1981; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/4\">",
"      Chaudhuri KR, Wren DR, Werring D, Watkins PJ. Unilateral abdominal muscle herniation with pain: a distinctive variant of diabetic radiculopathy. Diabet Med 1997; 14:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/5\">",
"      Longstreth GF. Diabetic thoracic polyradiculopathy: ten patients with abdominal pain. Am J Gastroenterol 1997; 92:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/6\">",
"      Lavy C, James A, Wilson-MacDonald J, Fairbank J. Cauda equina syndrome. BMJ 2009; 338:b936.",
"     </a>",
"    </li>",
"    <li>",
"     Kirkaldy-Willis WH, Yong-Hing K. Lateral recess, lateral canal, and foraminal stenosis. In: Lumbar Discectomy and Laminectomy, Watkins RG, Collis JS (Eds), Aspen Publishers, Rockville, MD. 1987. p.245.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/8\">",
"      Hunter AG, Bankier A, Rogers JG, et al. Medical complications of achondroplasia: a multicentre patient review. J Med Genet 1998; 35:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/9\">",
"      Hassan I. Cauda equina syndrome in ankylosing spondylitis: a report of six cases. J Neurol Neurosurg Psychiatry 1976; 39:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/10\">",
"      Tullous MW, Skerhut HE, Story JL, et al. Cauda equina syndrome of long-standing ankylosing spondylitis. Case report and review of the literature. J Neurosurg 1990; 73:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/11\">",
"      Hall S, Bartleson JD, Onofrio BM, et al. Lumbar spinal stenosis. Clinical features, diagnostic procedures, and results of surgical treatment in 68 patients. Ann Intern Med 1985; 103:271.",
"     </a>",
"    </li>",
"    <li>",
"     Marin-Padilla MD. The tethered cord syndrome: Developmental considerations. In: The Tethered Spinal Cord, Holtzman RNN, Stein BM (Eds), Thieme-Stratton, New York 1985. Vol 1, p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/13\">",
"      Caruso R, Cervoni L, Fiorenza F, et al. Occult dysraphism in adulthood. A series of 24 cases. J Neurosurg Sci 1996; 40:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/14\">",
"      Ratliff J, Mahoney PS, Kline DG. Tethered cord syndrome in adults. South Med J 1999; 92:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/15\">",
"      Aufschnaiter K, Fellner F, Wurm G. Surgery in adult onset tethered cord syndrome (ATCS): review of literature on occasion of an exceptional case. Neurosurg Rev 2008; 31:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/16\">",
"      Yamada S, Lonser RR. Adult tethered cord syndrome. J Spinal Disord 2000; 13:319.",
"     </a>",
"    </li>",
"    <li>",
"     Freeman TB, Cahill DW. Tumors of the meninges, cauda equina, and spinal nerves. In: Principles of Spinal Surgery, Menezes AH, Sonntag VK (Eds), McGraw-Hill, New York 1996. p.1371.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/18\">",
"      Fearnside MR, Adams CB. Tumours of the cauda equina. J Neurol Neurosurg Psychiatry 1978; 41:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/19\">",
"      Asazuma T, Toyama Y, Suzuki N, et al. Ependymomas of the spinal cord and cauda equina: An analysis of 26 cases and a review of the literature. Spinal Cord 1999; 37:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/20\">",
"      Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/21\">",
"      Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/22\">",
"      Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 9:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/23\">",
"      Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 2001; 3:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/24\">",
"      Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999; 53:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/25\">",
"      Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002; 25:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/26\">",
"      Halperin J, Luft BJ, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis. Peripheral nervous system manifestations. Brain 1990; 113 ( Pt 4):1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/27\">",
"      Garin C, Bujadoux A. Paralysis by ticks. 1922. Clin Infect Dis 1993; 16:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/28\">",
"      Reik L, Steere AC, Bartenhagen NH, et al. Neurologic abnormalities of Lyme disease. Medicine (Baltimore) 1979; 58:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/29\">",
"      Centers for Disease Control and Prevention (CDC). Lyme disease--United States, 2003-2005. MMWR Morb Mortal Wkly Rep 2007; 56:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/30\">",
"      Lakos A. CSF findings in Lyme meningitis. J Infect 1992; 25:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/31\">",
"      Pachner AR, Steere AC. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology 1985; 35:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/32\">",
"      Eidelberg D, Sotrel A, Vogel H, et al. Progressive polyradiculopathy in acquired immune deficiency syndrome. Neurology 1986; 36:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/33\">",
"      Miller RG, Storey JR, Greco CM. Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology 1990; 40:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/34\">",
"      Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 2000; 59:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/35\">",
"      Kim YS, Hollander H. Polyradiculopathy due to cytomegalovirus: report of two cases in which improvement occurred after prolonged therapy and review of the literature. Clin Infect Dis 1993; 17:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/36\">",
"      Meier PA, Stephan KT, Blatt SP. Cytomegalovirus polyradiculopathy in HIV-infected patients. J Gen Intern Med 1996; 11:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/37\">",
"      Fuller GN. Cytomegalovirus and the peripheral nervous system in AIDS. J Acquir Immune Defic Syndr 1992; 5 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/38\">",
"      Clifford DB, Buller RS, Mohammed S, et al. Use of polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with human immunodeficiency virus infection. Neurology 1993; 43:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/39\">",
"      Fisher MA. Electrophysiology of radiculopathies. Clin Neurophysiol 2002; 113:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/40\">",
"      American Association of Electrodiagnostic Medicine, So YT. Guidelines in electrodiagnostic medicine. Practice parameter for needle electromyographic evaluation of patients with suspected cervical radiculopathy. Muscle Nerve Suppl 1999; 8:S209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/41\">",
"      Nardin RA, Patel MR, Gudas TF, et al. Electromyography and magnetic resonance imaging in the evaluation of radiculopathy. Muscle Nerve 1999; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/42\">",
"      Haldeman S, Shouka M, Robboy S. Computed tomography, electrodiagnostic and clinical findings in chronic workers' compensation patients with back and leg pain. Spine (Phila Pa 1976) 1988; 13:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/43\">",
"      Khatri BO, Baruah J, McQuillen MP. Correlation of electromyography with computed tomography in evaluation of lower back pain. Arch Neurol 1984; 41:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/44\">",
"      Berger AR, Sharma K, Lipton RB. Comparison of motor conduction abnormalities in lumbosacral radiculopathy and axonal polyneuropathy. Muscle Nerve 1999; 22:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/45\">",
"      Kikuchi S, Sato K, Konno S, Hasue M. Anatomic and radiographic study of dorsal root ganglia. Spine (Phila Pa 1976) 1994; 19:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/46\">",
"      Marin R, Dillingham TR, Chang A, Belandres PV. Extensor digitorum brevis reflex in normals and patients with radiculopathies. Muscle Nerve 1995; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/47\">",
"      Tang LM, Schwartz MS, Swash M. Postural effects on F wave parameters in lumbosacral root compression and canal stenosis. Brain 1988; 111 ( Pt 1):207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/48\">",
"      So YT, Olney RK. Acute lumbosacral polyradiculopathy in acquired immunodeficiency syndrome: experience in 23 patients. Ann Neurol 1994; 35:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/14/14570/abstract/49\">",
"      Koffman B, Junck L, Elias SB, et al. Polyradiculopathy in sarcoidosis. Muscle Nerve 1999; 22:608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14149 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14570=[""].join("\n");
var outline_f14_14_14570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H85616251\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179604\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179611\">",
"      PRESENTATION BY SPINAL LEVEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179618\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179625\">",
"      Spinal stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179639\">",
"      Tethered cord syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179653\">",
"      Primary tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179667\">",
"      Leptomeningeal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179681\">",
"      Diabetic thoracic radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179695\">",
"      Diabetic amyotrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179709\">",
"      Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179723\">",
"      Polyradiculopathy in HIV and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179737\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179744\">",
"      Electrodiagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179751\">",
"      MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179758\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179765\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85616251\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14149|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/19/44339\" title=\"diagnostic image 1\">",
"      Multilevel spinal stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/32/20995\" title=\"diagnostic image 2\">",
"      Tethered cord syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/53/21329\" title=\"diagnostic image 3\">",
"      Multiple nerve root metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14149|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/8/21634\" title=\"figure 1\">",
"      Cervical dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/19/22836\" title=\"figure 2\">",
"      Thoracic dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/36/10822\" title=\"figure 3\">",
"      Lumbosacral dermatomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14149|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/52/25420\" title=\"table 1\">",
"      Motor weakness with nerve root lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/51/22333\" title=\"table 2\">",
"      Etiologies of polyradiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/4/33868\" title=\"table 3\">",
"      Symptoms and signs leptomeningeal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2987\" title=\"table 4\">",
"      PNS manifestations Lyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/35/22078\" title=\"table 5\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=related_link\">",
"      Acute lumbosacral radiculopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=related_link\">",
"      Cervical spondylotic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=related_link\">",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=related_link\">",
"      Diagnosis, treatment and prognosis of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=related_link\">",
"      Differential diagnosis of peripheral nerve and muscle disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15161?source=related_link\">",
"      Ependymoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=related_link\">",
"      Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=related_link\">",
"      Involvement of the central nervous system with acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=related_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22776?source=related_link\">",
"      Lumbar spinal stenosis: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=related_link\">",
"      Lumbosacral plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=related_link\">",
"      Nerve conduction studies: Late responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14681?source=related_link\">",
"      Nervous system Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42472?source=related_link\">",
"      Overview of soft tissue rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=related_link\">",
"      Pathogenesis and types of occult spinal dysraphism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17144?source=related_link\">",
"      Treatment of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_14_14571="Eso tests noncardiac chest pain";
var content_f14_14_14571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of comprehensive esophageal testing in 123 patients with chest pain and normal coronary arteriograms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent abnormal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambulatory esophageal pH monitoring",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal motility",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acid perfusion (Bernstein test)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edrophonium",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopy",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Balloon distention",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treadmill with pH monitor",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Cherian P, Smith LF, Bardhan KD, et al. Esophageal tests in the evaluation of non-cardiac chest pain. Dis Esophagus 1995; 8:129.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14571=[""].join("\n");
var outline_f14_14_14571=null;
var title_f14_14_14572="PegIFN Rx child HCV";
var content_f14_14_14572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Combination therapy with pegylated interferon and ribavirin for children 3 years and older with compensated HCV liver disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peginterferon*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pegylated interferon alfa-2b (PegIntron&reg;), 60 micrograms/m",
"        <sup>",
"         2",
"        </sup>",
"        subcutaneously once per week (maximum dose 1.5 micrograms/kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -- OR --&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pegylated interferon alfa-2a (Pegasys&reg;), 180 micrograms/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"        once per week (maximum dose 180 micrograms)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        and Ribavirin (Rebetol&reg; or Copegus&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15 mg/kg/day orally with food, divided into 2 doses",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Available as 200 mg capsules or 40 mg/ml oral solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Duration of therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        48 weeks for genotype 1",
"        <sup>",
"         &loz;&sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24 weeks may be sufficient for genotype 2 or 3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If depression develops, peginterferon should be given at a reduced dose (mild or moderate depression) or discontinued (severe depression).",
"     <br>",
"      &bull;&nbsp;For pegylated interferon alfa-2a&nbsp;(Pegasys&reg;), safety and efficacy have not been established for children younger than five years.&nbsp;",
"      <br>",
"       &Delta; If anemia develops, ribavirin should be given at a reduced dose (anemia alone), and discontinued (pancytopenia) (see package insert for parameters).",
"       <br>",
"        &loz;&nbsp;Earlier discontinuation of therapy is suggested if patients do not achieve at least a 2 log decrease in or loss of HCV-RNA after 12 weeks of therapy, or if HCV-RNA is detectable after 24 weeks of treatment (because these patients are unlikely to achieve sustained virologic response).",
"        <br>",
"         &sect; If possible, treatment of children with HCV genotype 1 might be deferred until triple therapy is available for children, or done sooner if under the auspices of a clinical trial",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from prescribing information for PegIntron&reg; package insert, approved 3/10/09; and for Pegasys&reg;, approved 8/2011.&nbsp;Available at: Drugs@FDA.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14572=[""].join("\n");
var outline_f14_14_14572=null;
var title_f14_14_14573="Onycho continuous safety";
var content_f14_14_14573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pooled risk estimates of safety outcomes for various regimens of continuous oral antifungal therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Study design",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        No. of arms/ patients included",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Treatment termination because of adverse effects (percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Transaminase elevation required treatment termination (percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Transaminase elevation did not require treatment termination (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pooled estimate",
"       </td>",
"       <td class=\"subtitle2\">",
"        95% CI",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pooled estimate",
"       </td>",
"       <td class=\"subtitle2\">",
"        95% CI",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pooled estimate",
"       </td>",
"       <td class=\"subtitle2\">",
"        95% CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Terbinafine",
"       </td>",
"       <td rowspan=\"2\">",
"        250 mg/d",
"       </td>",
"       <td>",
"        RCT",
"       </td>",
"       <td>",
"        41/3135",
"       </td>",
"       <td>",
"        3.44",
"       </td>",
"       <td>",
"        2.28-4.61",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td>",
"        0.09-0.60",
"       </td>",
"       <td>",
"        0.70",
"       </td>",
"       <td>",
"        0.08-1.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        57/3563",
"       </td>",
"       <td>",
"        3.45",
"       </td>",
"       <td>",
"        2.39-4.51",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.09-0.62",
"       </td>",
"       <td>",
"        0.70",
"       </td>",
"       <td>",
"        0.09-1.30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Itraconazole",
"       </td>",
"       <td rowspan=\"2\">",
"        100 mg/d",
"       </td>",
"       <td>",
"        RCT",
"       </td>",
"       <td>",
"        19/1002",
"       </td>",
"       <td>",
"        1.96",
"       </td>",
"       <td>",
"        0.35-3.57",
"       </td>",
"       <td>",
"        0.11",
"       </td>",
"       <td>",
"        0.00-0.32",
"       </td>",
"       <td>",
"        1.24",
"       </td>",
"       <td>",
"        0.00-2.64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        29/1307",
"       </td>",
"       <td>",
"        1.91",
"       </td>",
"       <td>",
"        0.59-3.23",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"       <td>",
"        0.00-0.25",
"       </td>",
"       <td>",
"        1.21",
"       </td>",
"       <td>",
"        0.15-2.28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        200 mg/d",
"       </td>",
"       <td>",
"        RCT",
"       </td>",
"       <td>",
"        12/2145",
"       </td>",
"       <td>",
"        4.21",
"       </td>",
"       <td>",
"        2.33-6.09",
"       </td>",
"       <td>",
"        0.70",
"       </td>",
"       <td>",
"        0.33-1.06",
"       </td>",
"       <td>",
"        1.90",
"       </td>",
"       <td>",
"        0.13-3.68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        14/2183",
"       </td>",
"       <td>",
"        3.94",
"       </td>",
"       <td>",
"        2.17-5.70",
"       </td>",
"       <td>",
"        0.68",
"       </td>",
"       <td>",
"        0.33-1.04",
"       </td>",
"       <td>",
"        1.98",
"       </td>",
"       <td>",
"        0.36-3.61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fluconazole",
"       </td>",
"       <td rowspan=\"2\">",
"        50 mg/d",
"       </td>",
"       <td>",
"        RCT",
"       </td>",
"       <td>",
"        3/235",
"       </td>",
"       <td>",
"        1.51",
"       </td>",
"       <td>",
"        0.00-4.01",
"       </td>",
"       <td>",
"        1.22",
"       </td>",
"       <td>",
"        0.00-5.30",
"       </td>",
"       <td>",
"        1.63",
"       </td>",
"       <td>",
"        0.00-5.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        5/879",
"       </td>",
"       <td>",
"        2.30",
"       </td>",
"       <td>",
"        0.93-3.66",
"       </td>",
"       <td>",
"        0.59",
"       </td>",
"       <td>",
"        0.00-1.79",
"       </td>",
"       <td>",
"        2.16",
"       </td>",
"       <td>",
"        0.02-4.30",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Adjusted Wald method for point estimate and CI.",
"    <div class=\"footnotes\">",
"     RCT: randomized controlled trial; CI: confidence interval; All: including randomized and nonrandomized controlled trials, case series, and cohort studies; NA: not available because not reported in the published literature.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chang, C-H, Young-Xu, Y, Kurth, T, et al. The Safety of Oral Antifungal Treatments for Superficial Dermatophytosis and Onychomycosis: A Meta-analysis. American Journal of Medicine 2007; 120:791. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14573=[""].join("\n");
var outline_f14_14_14573=null;
var title_f14_14_14574="Rate of prostate cancer";
var content_f14_14_14574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Rate of prostate cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age-adjusted rates of prostate cancer by stage and year of diagnosis in white men in the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) data base. Screening in the 1980s led to a progressive risk in the incidence of disease that was primarily organ-confined. The removal of these incidence cases led to a decline in new cases of prostate cancer after 1992. Screening also reduced the number of new cases presenting with distant metastases. Similar findings were noted in black men, except the absolute incidence of prostate cancer was higher.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Farkas, A, Schneider, D, Perrotti, M, et al, Urology 1998; 52:444.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14574=[""].join("\n");
var outline_f14_14_14574=null;
var title_f14_14_14575="Examination metacarpal malrotation 2";
var content_f14_14_14575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Second examination for metacarpal malrotation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this photograph, the hand is inspected for malrotation with the metacarpophalangeal joints flexed to 90 degrees while the proximal and distal interphalangeal joints are fully extended. In the absence of malrotation the plane of the fingernails should be aligned, as it is in this normal hand. The injured and contralateral hands can be compared.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_14_14575=[""].join("\n");
var outline_f14_14_14575=null;
